HIV SURVEILLANCE DATA TABLES

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative *(Early Release)*:

National HIV Surveillance System Data Reported through December 2020; and Preexposure Prophylaxis (PrEP) Data Reported through September 2020

Vol. 2, No. 2

Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2020 and preexposure prophylaxis (PrEP) data reported through September 2020.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (early release): National HIV Surveillance System data reported through December 2020; and preexposure prophylaxis (PrEP) data reported through September 2020. *HIV Surveillance Data Tables* 2021;2(No. 2). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published March 2021. Accessed [date].

On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Rick Song, Baohua Wu, Xiaohong Hu, Jianmin Li, Shihua Wang, Chan Jin, Chenchen Yu, Weiming Zhu, Anne Patala, Lei Yu, Norma Harris, and Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).

Contents

Technical Notes

The *Ending the HIV Epidemic: A Plan for America* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years and by at least 90% in 10 years. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress.

The included early release tables provide national-, state-, and county-level (EHE Phase I jurisdictions only; see Table 7) data for the 6 core indicators of the EHE initiative, which are the following:

- **New HIV infections**: the estimated number of new HIV infections in a calendar year.
- **Knowledge of HIV status**: the estimated percentage of persons with HIV who have received a diagnosis.
- **HIV diagnoses**: the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
- **Linkage to HIV medical care**: the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
- **HIV viral suppression**: the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
- **Preexposure prophylaxis (PrEP) coverage**: the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

Surveillance of HIV Infection

Data presented were reported (after the removal of personally identifiable information) to the Centers for Disease Control and Prevention (CDC) through December 31, 2020. Please use caution when interpreting the following:

- Data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.
- Deaths and prevalence-based data (knowledge of status and HIV viral suppression). Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020.
- Numbers less than 12 and trends based on these numbers.
- All data for the year 2020 are considered preliminary (provided using an NHSS dataset produced prior to reaching a 12-month reporting lag) and may be incomplete due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].

Tabulation and Presentation of Data

New HIV Infections

New HIV infections among persons aged ≥13 years are estimated by using the first CD4+ T-lymphocyte (CD4) test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infections can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-1.pdf (*Estimated HIV incidence and prevalence in the United States, 2014–2018*).

HIV Prevalence and Diagnosed Infection

The Knowledge of HIV Status indicator is measured as the percentage of persons aged ≥13 years with diagnosed HIV infection (Tables 2a–c). For this measure the numerator (data reported to CDC) is the number of persons aged ≥13 years living with diagnosed HIV infection at the end of the year. The denominator, total HIV prevalence, is the estimated number of persons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at the end of the year. Knowledge of status and prevalence data for the year 2019 are preliminary and based on death data reported

to CDC as of December 2020. The following areas had incomplete reporting of deaths for the year 2019 and prevalence estimates should be interpreted with caution: Kansas, Massachusetts, Mississippi, Nevada, North Dakota, and Vermont. Estimates for areas without laws requiring reporting of laboratory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV infection can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-1 (*Estimated HIV incidence and prevalence in the United States, 2014–2018*).

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years with HIV diagnosed during 2017–2020 (Tables 3a–d).

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-31.pdf (*HIV Surveillance Report, 2018 [Updated]*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose infection was diagnosed during January 2019 through September 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period, and who had ≥1 CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period.

Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through September of 2020 and that were reported to NHSS through December 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached; preliminary data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

More information on calculating linkage to care can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018*).

Viral Suppression

Viral suppression at most recent test during the specified year is measured for persons aged ≥13 years who resided, as of their most recent known address during the specified year, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC, and who were alive at the end of the specified year (Tables 5a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed by the end of the prior year, and who had a VL of < 200 copies/mL at the most recent test in the specified year. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed by the end of the prior year, and who were alive at the end of the specified year. Viral suppression data for the year 2019 are preliminary. Data used to calculate prevalence are based on deaths reported to CDC as of December 2020. The following areas had incomplete reporting of deaths for the year 2019 and viral suppression data should be

interpreted with caution: Kansas, Massachusetts, Mississippi, Nevada, North Dakota, and Vermont. Data are not provided for states and associated EHE Phase I jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

More information on calculating viral suppression can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018*).

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 6a–6c).

Number of persons prescribed, which is reported as a case count, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year.

PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include white, black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S Department of Housing and Urban Development's ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [8, 9]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for

PrEP [10]. For the 2018 denominator, this proportion was updated with recent NHANES data.

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [10]. Jurisdictional estimates were rounded to the nearest 10. Beginning in 2017, methods were adjusted to provide the estimated number of persons of other races/ethnicities (including Asians and other race/ethnic groups), in addition to Blacks/African Americans, Hispanics/Latinos, and whites. Also beginning in 2017, an adjustment was applied to calculate an estimated number of persons with PrEP indications in counties with suppressed data for the number of HIV diagnoses in some transmission risk groups, age groups, or race/ethnicity groups.

The tables included in this report provide updated data on PrEP coverage for the years 2017 and 2018 and preliminary data for the year 2019 and for the year 2020 (from January through September) using the IQVIA data reported through September 2020. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary. For this release of *HIV Surveillance Data Tables*, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

More information on calculating PrEP coverage can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018*).

REFERENCES

1. HHS. What is 'Ending the HIV Epidemic: A Plan for America'? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Published October 4, 2019. Accessed March 11, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2
3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
6. U.S. Census Bureau. American Community Survey 5-year data (2009–2018). https://www.census.gov/data/developers/data-sets/acs-5year.2018.html. Published December 19, 2019. Accessed March 11, 2021.
7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Published 2019. Accessed March 11, 2021.
8. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14.
9. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107.
10. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

Table 1a. Estimated HIV incidence among persons aged ≥13 years, by selected characteristics, 2017–2019—United States

	2017			2018			2019		
	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
Sex at birth									
Male	30,000	2.7	28,400–31,600	29,600	3.2	27,700–31,400	28,400	3.8	26,300–30,500
Female	6,700	5.1	6,100–7,400	6,700	5.7	5,900–7,400	6,400	6.6	5,600–7,200
Age at infection (yr)									
13–24	8,600	4.9	7,700–9,400	7,800	6.1	6,800–8,700	7,200	7.4	6,200–8,300
25–34	14,100	3.9	13,000–15,200	14,300	4.5	13,000–15,500	13,800	5.3	12,400–15,300
35–44	6,700	5.6	5,900–7,400	6,900	6.4	6,100–7,800	6,900	7.4	5,900–7,900
45–54	4,400	6.9	3,800–5,000	4,200	8.1	3,600–4,900	3,800	9.9	3,100–4,600
≥55	3,000	8.5	2,500–3,400	3,100	9.5	2,500–3,600	3,100	10.9	2,400–3,800
Race/ethnicity									
American Indian/Alaska Native	190	*33.5	70–320	210	*37.8	50–370	230	*41.2	40–420
Asian	620	19.2	380–850	580	23.2	320–850	550	26.8	260–840
Black/African American	14,900	3.7	13,800–16,000	14,800	4.3	13,500–16,000	14,300	5.1	12,900–15,700
Hispanic/Latino[a]	10,800	4.7	9,800–11,800	11,000	5.5	9,800–12,200	10,200	6.7	8,900–11,600
Native Hawaiian/other Pacific Islander	…	…	…	…	…	…	…	…	…
White	9,100	4.5	8,300–9,800	8,700	5.3	7,800–9,600	8,600	6.1	7,600–9,600
Multiracial	1,100	14.3	810–1,400	940	17.9	610–1,300	900	20.9	530–1,300
Transmission category[b]									
Male-to-male sexual contact	24,900	2.9	23,400–26,300	24,100	3.5	22,500–25,800	23,100	4.2	21,200–25,000
Injection drug use	2,300	8.5	1,900–2,700	2,500	9.5	2,000–3,000	2,500	11.3	1,900–3,000
Male	1,300	12.3	970–1,600	1,500	13.2	1,100–1,800	1,400	16.2	940–1,800
Female	1,000	11.2	810–1,300	1,000	13.1	770–1,300	1,100	15.4	750–1,400
Male-to-male sexual contact and injection drug use	1,300	11.1	1,000–1,600	1,400	11.8	1,100–1,800	1,400	13.4	1,100–1,800
Heterosexual contact[c]	8,200	5.3	7,300–9,000	8,200	5.9	7,200–9,100	7,800	6.8	6,700–8,800
Male	2,500	11.5	1,900–3,100	2,600	12.7	1,900–3,200	2,400	14.5	1,700–3,100
Female	5,700	5.6	5,000–6,300	5,600	6.4	4,900–6,300	5,300	7.4	4,600–6,100
Region of residence									
Northeast	5,100	6.4	4,500–5,800	4,900	7.5	4,200–5,600	4,700	9.1	3,900–5,500
Midwest	4,900	6.5	4,200–5,500	4,700	7.6	4,000–5,400	4,500	9.0	3,700–5,300
South	19,200	3.3	17,900–20,400	19,100	3.9	17,600–20,500	18,500	4.5	16,800–20,100
West	7,500	5.3	6,800–8,300	7,600	6.2	6,700–8,500	7,100	7.4	6,100–8,200
Total[d]	**36,700**	**2.4**	**35,000–38,400**	**36,200**	**2.8**	**34,300–38,200**	**34,800**	**3.3**	**32,600–37,100**

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.

Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Hispanic/Latino persons can be of any race.

[b] Data by transmission category have been statistically adjusted to account for missing risk-factor information.

[c] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[d] Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or identified.

Table 1b. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2019—United States and Puerto Rico

	2017			2018			2019		
Area of residence	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**
Alabama	630	18.1	400–850	600	21.3	350–850	570	25.7	280–860
Alaska	…	…	…	…	…	…	…	…	…
Arizona	840	16.4	570–1,100	870	19.0	550–1,200	800	23.2	440–1,200
Arkansas	300	28.0	130–460	240	*37.3	60–410	330	*35.3	100–560
California	4,600	6.6	4,000–5,200	4,500	7.6	3,900–5,200	4,000	9.6	3,300–4,800
Colorado	440	22.4	250–630	430	26.5	210–650	510	28.2	230–800
Connecticut	250	28.6	110–380	190	*39.4	40–340	160	*49.4	0–320
Delaware	120	*36.8	30–210	…	…	…	…	…	…
District of Columbia	210	29.7	90–330	230	29.9	100–370	190	*38.2	50–330
Florida	4,400	6.4	3,900–5,000	4,300	7.5	3,700–4,900	4,000	8.9	3,300–4,700
Georgia	2,500	9.2	2,100–3,000	2,500	11.0	2,000–3,000	2,400	13.1	1,800–3,000
Hawaii	100	*44.8	10–180	…	…	…	…	…	…
Idaho[a]	…	…	…	…	…	…	…	…	…
Illinois	1,300	12.6	970–1,600	1,300	14.4	930–1,700	1,200	17.7	790–1,600
Indiana	530	21.1	310–750	580	22.6	330–840	540	28.3	240–850
Iowa	100	*49.9	0–210	…	…	…	…	…	…
Kansas[a]	…	…	…	…	…	…	210	*42.3	40–390
Kentucky[a]	310	26.1	150–470	420	24.2	220–620	340	*33.1	120–560
Louisiana	1,000	15.0	700–1,300	1,100	16.5	720–1,400	870	22.3	490–1,300
Maine	…	…	…	…	…	…	…	…	…
Maryland	760	16.7	510–1,000	830	17.2	550–1,100	740	21.0	430–1,000
Massachusetts	570	18.3	360–770	680	18.2	430–920	530	24.6	270–780
Michigan	720	17.3	470–960	670	20.8	400–950	630	25.0	320–930
Minnesota	250	29.2	110–390	290	*31.4	110–470	260	*37.8	70–450
Mississippi	480	26.1	230–720	440	*32.4	160–720	550	*32.9	190–900
Missouri	520	17.9	340–700	480	22.5	270–690	450	26.3	220–680
Montana	…	…	…	…	…	…	…	…	…
Nebraska	110	*42.9	20–200	…	…	…	…	…	…
Nevada	570	20.9	330–800	610	23.3	330–890	740	25.0	380–1,100
New Hampshire	…	…	…	…	…	…	…	…	…
New Jersey[a]	1,100	15.6	750–1,400	960	19.0	600–1,300	990	20.8	590–1,400
New Mexico	140	*35.6	40–230	180	*35.7	60–310	170	*44.0	20–310
New York	2,200	9.5	1,800–2,600	2,000	11.5	1,600–2,500	1,800	13.9	1,300–2,300
North Carolina	1,200	12.0	900–1,500	1,100	14.7	760–1,400	1,200	14.9	860–1,600

Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2019—United States and Puerto Rico *(cont)*

	2017			2018			2019		
Area of residence	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**
North Dakota	…	…	…	…	…	…	…	…	…
Ohio	970	14.7	690–1,300	890	17.8	580–1,200	870	20.6	520–1,200
Oklahoma	320	25.1	160–470	300	*31.6	110–490	370	*33.3	130–610
Oregon	210	*31.9	80–340	190	*39.5	*40–340	200	*44.1	30–380
Pennsylvania[a]	970	19.0	610–1,300	980	20.5	590–1,400	800	22.1	450–1,100
Puerto Rico[a]	400	22.9	220–580	320	28.7	140–510	280	*35.4	90–480
Rhode Island	80	*47.2	10–150	…	…	…	…	…	…
South Carolina	700	19.3	430–960	690	22.8	380–1,000	710	25.5	350–1,100
South Dakota	…	…	…	…	…	…	…	…	…
Tennessee	700	15.7	490–920	660	18.6	420–900	710	19.6	440–980
Texas	4,400	6.9	3,800–5,000	4,500	7.8	3,800–5,200	4,500	9.2	3,700–5,300
Utah	110	*42.6	20–200	130	*43.2	20–250	150	*47.3	10–290
Vermont[a]	…	…	…	…	…	…	…	…	…
Virginia	850	15.3	600–1,100	800	18.1	520–1,100	760	21.2	440–1,100
Washington	480	21.2	280–680	520	23.3	280–760	540	27.3	250–830
West Virginia	80	*50.0	0–170	110	*48.1	10–220	210	*40.7	40–380
Wisconsin	240	28.2	110–370	190	*38.5	50–330	210	*41.1	40–370
Wyoming	…	…	…	…	…	…	…	…	…

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.

Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Table 1c. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions

	2017			2018			2019		
Area of residence	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**
Arizona									
Maricopa County	560	19.2	350–760	560	22.4	320–810	520	27.6	240–800
California									
Alameda County	180	*32.6	60–290	180	*36.7	50–320	200	*41.3	40–360
Los Angeles County	1,400	11.4	1,100–1,800	1,400	13.1	1,100–1,800	1,300	16.0	900–1,700
Orange County	270	26.3	130–410	270	*30.4	110–430	200	*40.7	40–370
Riverside County	270	26.5	130–410	270	*30.0	110–440	260	*35.9	80–440
Sacramento County	220	29.2	90–350	160	*39.4	40–280	140	*48.6	10–280
San Bernardino County	260	26.9	120–400	240	*31.9	90–390	300	*33.6	100–490
San Diego County	450	20.5	270–630	430	24.2	220–630	360	*30.7	140–570
San Francisco County	170	*33.3	60–280	150	*40.4	30–270	…	…	…
District of Columbia	210	29.7	90–330	230	29.9	100–370	190	*38.2	50–330
Florida									
Broward County	650	16.0	450–860	550	20.0	340–770	560	22.8	310–810
Duval County	260	25.5	130–390	230	*31.0	90–370	190	*39.2	40–340
Hillsborough County	290	24.2	150–420	270	28.4	120–430	210	*37.1	60–370
Miami-Dade County	1,200	12.0	890–1,400	1,100	13.9	840–1,500	1,100	16.4	740–1,400
Orange County	430	19.8	260–600	450	22.2	250–650	450	25.4	230–680
Palm Beach County	260	25.3	130–390	250	29.8	100–400	230	*36.0	70–390
Pinellas County	150	*33.6	50–250	140	*40.2	30–240	150	*44.6	20–280
Georgia									
Cobb County	170	*33.2	60–290	160	*41.6	30–280	220	*41.3	40–390
DeKalb County	340	23.8	180–500	390	26.2	190–590	330	*33.4	110–550
Fulton County	570	18.4	360–770	620	20.8	370–870	500	27.2	230–770
Gwinnett County	160	*34.4	50–270	140	*43.6	20–260	200	*42.7	30–370
Illinois									
Cook County	940	14.5	680–1,200	890	17.4	580–1,200	870	20.7	520–1,200
Indiana									
Marion County	230	29.0	100–350	250	*31.4	100–400	250	*38.9	60–430
Louisiana									
East Baton Rouge Parish	180	*31.5	70–290	190	*34.3	60–320	180	*42.1	30–330
Orleans Parish	160	*32.8	60–270	160	*37.6	40–280	140	*47.6	10–270
Maryland									
Baltimore City	190	*34.1	60–310	210	*34.0	70–350	140	*49.0	10–280
Montgomery County	110	*45.0	10–200	…	…	…	…	…	…
Prince George's County	190	*33.7	60–320	260	*30.3	110–420	240	*37.2	70–420
Massachusetts									
Suffolk County	130	*36.7	40–230	140	*37.8	40–250	140	*43.5	20–260

Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

	2017			2018			2019		
Area of residence	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**	**No.**	**RSE (%)**	**95% CI**
Michigan									
Wayne County	290	24.8	150–430	270	29.8	110–430	300	*32.9	100–490
Nevada									
Clark County	500	21.8	290–720	550	24.1	290–820	630	27.0	300–970
New Jersey									
Essex County[a]	310	26.6	150–480	230	*36.5	70–390	210	*43.5	30–390
Hudson County[a]	160	*37.5	40–280	170	*41.7	30–320	…	…	…
New York									
Bronx County	380	21.8	220–550	410	24.0	220–600	400	28.7	170–620
Kings County	490	19.2	310–680	470	22.6	260–670	370	29.6	160–590
New York County	340	23.0	190–500	280	28.9	120–440	270	*35.1	80–450
Queens County	340	23.3	180–490	300	28.2	130–460	220	*38.7	50–380
North Carolina									
Mecklenburg County	270	22.9	150–400	190	*36.4	50–330	220	*35.2	70–380
Ohio									
Cuyahoga County	140	*39.4	30–240	110	*49.8	0–220	…	…	…
Franklin County	200	*32.2	80–330	210	*35.9	60–360	210	*40.7	40–390
Hamilton County	170	*35.5	50–290	150	*43.1	20–280	…	…	…
Pennsylvania									
Philadelphia County	400	18.5	260–550	400	20.9	230–560	400	23.9	210–580
Puerto Rico									
San Juan Municipio[a]	100	*43.5	10–180	…	…	…	…	…	…
Tennessee									
Shelby County	220	27.9	100–330	220	29.5	90–350	230	*32.0	90–370
Texas									
Bexar County	310	25.7	150–460	340	28.3	150–520	380	*31.5	140–610
Dallas County	810	15.8	560–1,100	820	18.1	530–1,100	610	24.9	310–900
Harris County	1,100	13.3	840–1,400	1,200	15.1	840–1,500	1,200	17.6	800–1,600
Tarrant County	300	25.8	150–460	270	*31.4	100–440	340	*33.2	120–560
Travis County	210	*31.0	80–340	240	*33.3	*80–400	190	*44.9	20–350
Washington									
King County	220	*31.1	80–350	290	*30.0	120–460	240	*41.9	40–450

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: New Jersey. Areas with incomplete reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2109—United States

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2017						
Sex at birth							
Male	889,600	0.4	883,200–896,000	756,245	85.0	0.4	84.4–85.6
Female	257,500	0.6	254,300–260,600	229,677	89.2	0.6	88.1–90.3
Age (yr)							
13–24	58,300	1.3	56,800–59,800	27,471	47.1	1.3	45.9–48.4
25–34	206,800	0.6	204,400–209,200	148,259	71.7	0.6	70.9–72.5
35–44	219,100	0.5	217,100–221,200	187,196	85.4	0.5	84.6–86.2
45–54	316,300	0.4	314,000–318,600	292,913	92.6	0.4	91.9–93.3
≥55	346,500	0.4	343,500–349,500	330,083	95.3	0.4	94.5–96.1
Race/ethnicity							
American Indian/Alaska Native	3,700	5.8	3,200–4,100	2,890	79.1	5.9	71.0–89.2
Asian[b]	16,500	2.4	15,700–17,300	13,703	83.0	2.4	79.2–87.1
Black/African American	462,800	0.5	458,200–467,300	396,794	85.7	0.5	84.9–86.6
Hispanic/Latino[c]	277,000	0.6	273,700–280,400	229,451	82.8	0.6	81.8–83.8
Native Hawaiian/other Pacific Islander	1,000	10.4	800–1,200	800	79.2	10.9	65.7–99.6
White	331,100	0.6	327,100–335,000	293,375	88.6	0.6	87.6–89.7
Multiracial	54,300	1.3	52,900–55,700	48,185	88.8	1.3	86.6–91.1
Transmission category[d]							
Male-to-male sexual contact	657,800	0.4	652,500–663,100	551,337	83.8	0.4	83.1–84.5
Injection drug use	126,100	1.1	123,400–128,800	117,609	93.3	1.1	91.3–95.3
Male	73,900	1.5	71,800–76,100	68,695	93.0	1.5	90.3–95.7
Female	52,200	1.5	50,600–53,800	48,914	93.7	1.5	90.9–96.6
Male-to-male sexual contact and injection drug use	61,600	1.4	59,900–63,200	56,526	91.8	1.4	89.4–94.3
Heterosexual contact[e]	298,200	0.6	294,700–301,700	257,233	86.3	0.6	85.3–87.3
Male	94,300	1.2	92,100–96,400	77,740	82.5	1.2	80.6–84.4
Female	203,900	0.7	201,200–206,700	179,492	88.0	0.7	86.9–89.2
Region of residence							
Northeast	250,900	0.7	247,500–254,300	227,889	90.8	0.7	89.6–92.1
Midwest	139,900	0.9	137,400–142,400	117,771	84.2	0.9	82.7–85.7
South	527,400	0.5	522,600–532,200	444,756	84.3	0.5	83.6–85.1
West	228,900	0.7	225,700–232,000	195,506	85.4	0.7	84.3–86.6
Total[f]	**1,147,100**	**0.3**	**1,139,900–1,154,200**	**985,922**	**86.0**	**0.3**	**85.4–86.5**

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2109—United States *(cont)*

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2018						
Sex at birth							
Male	908,000	0.4	901,400–914,700	775,373	85.4	0.4	84.8–86.0
Female	260,600	0.6	257,400–263,900	233,277	89.5	0.6	88.4–90.6
Age (yr)							
13–24	51,800	1.6	50,200–53,400	26,319	50.8	1.6	49.2–52.5
25–34	214,000	0.7	211,200–216,700	153,015	71.5	0.7	70.6–72.4
35–44	222,900	0.5	220,600–225,200	189,585	85.0	0.5	84.2–85.9
45–54	303,500	0.4	301,100–305,900	280,939	92.6	0.4	91.8–93.3
≥55	376,500	0.4	373,300–379,600	358,792	95.3	0.4	94.5–96.1
Race/ethnicity							
American Indian/Alaska Native	3,800	5.9	3,400–4,300	3,026	79.2	6.0	70.9–89.6
Asian[b]	17,100	2.5	16,300–17,900	14,556	85.1	2.5	81.2–89.5
Black/African American	471,100	0.5	466,400–475,800	405,759	86.1	0.5	85.3–87.0
Hispanic/Latino[c]	286,000	0.6	282,400–289,600	237,914	83.2	0.6	82.2–84.3
Native Hawaiian/other Pacific Islander	1,100	10.8	850–1,300	853	81.0	10.4	66.8–100
White	334,800	0.6	330,700–338,800	297,674	88.9	0.6	87.9–90.0
Multiracial	54,200	1.4	52,700–55,600	48,144	88.9	1.4	86.6–91.3
Transmission category[d]							
Male-to-male sexual contact	675,700	0.4	670,100–681,300	569,690	84.3	0.4	83.6–85.0
Injection drug use	125,300	1.1	122,600–128,000	116,779	93.2	1.1	91.2–95.3
Male	73,300	1.5	71,100–75,500	68,046	92.8	1.5	90.1–95.7
Female	52,000	1.6	50,400–53,600	48,733	93.7	1.6	90.9–96.7
Male-to-male sexual contact and injection drug use	61,600	1.4	59,900–63,300	56,545	91.8	1.4	89.3–94.3
Heterosexual contact[e]	302,700	0.6	299,100–306,300	262,443	86.7	0.6	85.7–87.8
Male	95,300	1.2	93,100–97,600	79,170	83.0	1.2	81.1–85.0
Female	207,400	0.7	204,500–210,200	183,273	88.4	0.7	87.2–89.6
Region of residence							
Northeast	252,300	0.7	248,900–255,800	229,996	91.1	0.7	89.9–92.4
Midwest	142,700	0.9	140,100–145,300	120,835	84.7	0.9	83.2–86.2
South	539,400	0.5	534,300–544,400	456,972	84.7	0.5	83.9–85.5
West	234,300	0.7	231,000–237,500	200,847	85.7	0.7	84.5–87.0
Total[f]	**1,168,700**	**0.3**	**1,161,200–1,176,100**	**1,008,650**	**86.3**	**0.3**	**85.8–86.9**

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2109—United States *(cont)*

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2019						
Sex at birth							
Male	925,800	0.4	918,800–932,800	794,128	85.8	0.4	85.1–86.4
Female	263,900	0.7	260,600–267,300	237,063	89.8	0.7	88.7–91.0
Age (yr)							
13–24	45,900	2.0	44,100–47,700	25,581	55.7	2.0	53.6–58.0
25–34	218,700	0.7	215,600–221,800	156,378	71.5	0.7	70.5–72.5
35–44	228,000	0.6	225,500–230,500	192,894	84.6	0.6	83.7–85.6
45–54	290,000	0.4	287,500–292,400	268,039	92.4	0.4	91.7–93.2
≥55	407,100	0.4	403,800–410,400	388,299	95.4	0.4	94.6–96.2
Race/ethnicity							
American Indian/Alaska Native	4,000	6.2	3,500–4,500	3,185	79.5	6.3	71.0–90.5
Asian[b]	17,700	2.6	16,800–18,600	15,309	86.6	2.6	82.5–91.2
Black/African American	479,300	0.5	474,400–484,300	415,003	86.6	0.5	85.7–87.5
Hispanic/Latino[c]	294,200	0.7	290,400–298,100	246,078	83.6	0.7	82.6–84.7
Native Hawaiian/other Pacific Islander	1,100	11.2	910–1,300	906	83.6	9.6	68.5–100
White	338,600	0.6	334,400–342,800	301,927	89.2	0.6	88.1–90.3
Multiracial	54,100	1.4	52,600–55,500	48,063	88.9	1.4	86.5–91.4
Transmission category[d]							
Male-to-male sexual contact	692,900	0.4	686,900–698,800	587,555	84.8	0.4	84.1–85.5
Injection drug use	124,700	1.1	122,000–127,500	116,263	93.2	1.1	91.2–95.3
Male	72,900	1.6	70,600–75,100	67,603	92.8	1.6	90.0–95.7
Female	51,900	1.6	50,200–53,500	48,660	93.8	1.6	90.9–96.8
Male-to-male sexual contact and injection drug use	61,800	1.4	60,000–63,500	56,720	91.8	1.4	89.3–94.5
Heterosexual contact[e]	307,000	0.6	303,300–310,800	267,478	87.1	0.6	86.1–88.2
Male	96,300	1.2	93,900–98,600	80,351	83.4	1.2	81.5–85.5
Female	210,700	0.7	207,800–213,700	187,127	88.8	0.7	87.6–90.1
Region of residence							
Northeast	253,600	0.7	250,000–257,200	231,873	91.4	0.7	90.1–92.7
Midwest	145,100	0.9	142,500–147,800	123,501	85.1	0.9	83.5–86.7
South	551,600	0.5	546,300–556,900	469,803	85.2	0.5	84.4–86.0
West	239,400	0.7	235,900–242,800	206,014	86.1	0.7	84.8–87.3
Total[f]	**1,189,700**	**0.3**	**1,181,900–1,197,500**	**1,031,191**	**86.7**	**0.3**	**86.1–87.2**

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Reported to the National HIV Surveillance System.

[b] Includes Asian/Pacific Islander legacy cases.

[c] Hispanic/Latino persons can be of any race.

[d] Data by transmission category have been statistically adjusted to account for missing risk-factor information.

[e] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or not identified.

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—United States and Puerto Rico

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2017						
Alabama	15,700	2.7	14,900–16,600	12,930	82.1	2.7	78.0–86.8
Alaska	810	11.4	700–990	704	87.1	8.4	71.2–100
Arizona	18,900	2.4	18,100–19,800	15,727	83.0	2.4	79.3–87.0
Arkansas	6,900	4.0	6,300–7,400	5,534	80.6	4.0	74.7–87.5
California	146,400	0.9	143,800–148,900	127,097	86.8	0.9	85.4–88.4
Colorado	14,000	2.7	13,300–14,700	12,106	86.6	2.7	82.2–91.3
Connecticut	11,300	3.2	10,600–12,000	10,144	89.9	3.2	84.6–95.9
Delaware	3,600	5.5	3,200–4,000	3,219	88.4	5.6	79.8–99.2
District of Columbia	15,100	2.8	14,300–15,900	14,066	93.3	2.8	88.5–98.7
Florida	125,700	1.0	123,400–128,100	107,614	85.6	1.0	84.0–87.2
Georgia	63,400	1.3	61,800–64,900	52,366	82.7	1.3	80.6–84.8
Hawaii	2,800	6.4	2,400–3,100	2,413	87.1	6.6	77.4–99.8
Idaho[b]	1,400	10.1	1,100–1,600	1,109	81.5	10.0	68.0–100
Illinois	40,300	1.7	39,000–41,600	34,661	86.0	1.7	83.2–89.0
Indiana	13,200	2.9	12,500–14,000	10,945	82.7	2.9	78.3–87.7
Iowa	3,100	5.5	2,800–3,500	2,638	84.0	5.6	75.7–94.2
Kansas[b,c]	3,600	5.7	3,200–4,000	2,959	82.2	5.8	73.9–92.6
Kentucky[b]	8,500	3.5	7,900–9,000	7,000	82.6	3.5	77.4–88.6
Louisiana	24,400	2.2	23,300–25,500	20,129	82.5	2.3	79.0–86.3
Maine	1,800	7.7	1,500–2,000	1,545	87.4	7.0	76.0–100
Maryland	36,300	1.8	35,100–37,600	32,116	88.4	1.8	85.4–91.6
Massachusetts[c]	22,400	2.2	21,500–23,400	20,032	89.4	2.2	85.8–93.4
Michigan	18,600	2.6	17,700–19,600	15,471	83.0	2.6	79.1–87.5
Minnesota	9,400	3.2	8,800–10,000	8,155	86.9	3.2	81.8–92.7
Mississippi[c]	11,600	3.4	10,800–12,300	9,203	79.6	3.4	74.6–85.3
Missouri	14,000	2.8	13,200–14,800	12,149	86.8	2.8	82.3–91.8
Montana	710	10.6	620–850	615	87.0	8.2	72.0–100
Nebraska	2,500	6.4	2,200–2,800	2,087	84.1	6.5	74.8–96.2
Nevada[c]	11,700	3.0	11,000–12,400	9,473	81.0	3.0	76.6–86.1
New Hampshire	1,300	8.8	1,200–1,500	1,161	89.7	6.7	76.4–100
New Jersey[b]	38,800	1.9	37,300–40,300	34,058	87.8	2.0	84.6–91.3
New Mexico	3,900	4.9	3,500–4,300	3,385	86.4	4.9	78.8–95.6
New York	133,800	0.9	131,400–136,300	123,071	92.0	0.9	90.3–93.7
North Carolina	35,300	1.7	34,100–36,400	30,468	86.4	1.7	83.6–89.3
North Dakota[c]	620	16.2	420–820	400	64.3	18.1	48.7–94.3
Ohio	26,000	2.0	25,000–27,000	21,663	83.4	2.0	80.2–86.8
Oklahoma	7,200	4.0	6,600–7,800	5,942	82.6	4.1	76.6–89.7
Oregon	7,800	3.5	7,300–8,300	6,822	87.6	3.5	81.9–94.0
Pennsylvania[b]	39,200	1.8	37,900–40,600	34,703	88.5	1.8	85.5–91.7
Puerto Rico[b]	17,500	3.1	16,500–18,600	15,665	89.4	3.1	84.3–95.1
Rhode Island	2,800	6.0	2,500–3,100	2,497	88.7	6.0	79.3–100
South Carolina	19,900	2.4	18,900–20,800	16,466	82.8	2.4	79.0–86.9
South Dakota	740	12.5	570–920	567	76.5	12.8	61.5–100
Tennessee	19,400	2.4	18,500–20,300	16,461	85.0	2.4	81.2–89.2
Texas	106,000	1.0	103,900–108,100	87,393	82.5	1.0	80.9–84.1
Utah	3,200	5.7	2,900–3,600	2,718	83.8	5.7	75.4–94.2
Vermont[b,c]	770	10.5	680–920	678	88.5	7.7	73.4–100
Virginia	25,600	2.1	24,600–26,700	22,073	86.1	2.1	82.7–89.7
Washington	15,000	2.6	14,200–15,700	13,019	87.1	2.6	82.8–91.8
West Virginia	2,100	7.1	1,800–2,400	1,776	83.1	7.3	72.9–96.6
Wisconsin	7,000	3.8	6,500–7,600	6,076	86.3	3.8	80.3–93.2
Wyoming	370	16.1	320–480	318	87.0	9.9	66.1–100

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—United States and Puerto Rico *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2018						
Alabama	16,200	2.8	15,300–17,100	13,371	82.6	2.8	78.4–87.4
Alaska	810	11.8	700–1,000	697	86.3	8.9	70.0–100
Arizona	19,700	2.4	18,800–20,600	16,357	83.1	2.4	79.3–87.2
Arkansas	7,000	4.2	6,400–7,500	5,670	81.4	4.2	75.3–88.7
California	148,900	0.9	146,200–151,500	129,772	87.2	0.9	85.7–88.7
Colorado	14,500	2.7	13,700–15,200	12,552	86.8	2.7	82.4–91.7
Connecticut	11,400	3.3	10,600–12,100	10,284	90.6	3.3	85.1–96.8
Delaware	3,700	5.7	3,300–4,100	3,246	88.7	5.7	79.8–99.8
District of Columbia	14,900	2.8	14,100–15,700	13,940	93.6	2.9	88.7–99.1
Florida	127,600	1.0	125,100–130,000	109,691	86.0	1.0	84.4–87.7
Georgia	65,200	1.3	63,500–66,900	54,219	83.1	1.3	81.1–85.3
Hawaii	2,700	6.8	2,400–3,100	2,358	87.5	6.7	77.1–100
Idaho[b]	1,400	10.6	1,200–1,700	1,155	81.5	10.2	67.5–100
Illinois	41,000	1.7	39,700–42,400	35,482	86.4	1.7	83.6–89.5
Indiana	13,600	3.0	12,900–14,400	11,289	82.7	3.0	78.1–87.9
Iowa	3,300	5.7	2,900–3,600	2,750	84.3	5.8	75.8–94.9
Kansas[b,c]	3,700	6.0	3,200–4,100	3,044	83.3	6.1	74.6–94.3
Kentucky[b]	8,800	3.5	8,200–9,400	7,264	82.7	3.6	77.3–88.9
Louisiana	25,000	2.3	23,900–26,100	20,609	82.5	2.3	78.9–86.4
Maine	1,800	7.8	1,600–2,100	1,594	87.9	6.9	76.2–100
Maryland	36,700	1.8	35,400–38,000	32,645	88.9	1.8	85.9–92.2
Massachusetts[c]	22,700	2.2	21,800–23,700	20,344	89.5	2.2	85.8–93.5
Michigan	18,900	2.6	17,900–19,900	15,782	83.5	2.7	79.4–88.1
Minnesota	9,700	3.3	9,000–10,300	8,431	87.3	3.3	82.0–93.2
Mississippi[c]	11,700	3.6	10,900–12,500	9,395	80.2	3.6	74.9–86.3
Missouri	14,300	2.8	13,500–15,100	12,461	86.9	2.8	82.3–92.0
Montana	730	10.8	640–890	638	87.1	8.3	71.8–100
Nebraska	2,500	6.6	2,200–2,800	2,133	85.0	6.7	75.2–97.6
Nevada[c]	12,400	3.0	11,700–13,200	10,085	81.2	3.1	76.7–86.4
New Hampshire	1,300	8.7	1,200–1,600	1,227	91.0	6.2	77.7–100
New Jersey[b]	38,800	2.0	37,300–40,400	34,171	88.0	2.0	84.6–91.6
New Mexico	4,100	4.9	3,700–4,500	3,564	86.0	4.9	78.4–95.1
New York	134,100	0.9	131,600–136,600	123,796	92.3	0.9	90.6–94.0
North Carolina	36,100	1.7	34,800–37,300	31,371	87.0	1.7	84.2–90.0
North Dakota[c]	690	17.2	450–920	440	64.1	19.5	47.9–96.7
Ohio	26,500	2.1	25,400–27,500	22,215	84.0	2.1	80.7–87.6
Oklahoma	7,400	4.1	6,800–8,000	6,109	82.8	4.2	76.6–90.1
Oregon	7,900	3.6	7,400–8,500	7,008	88.3	3.6	82.5–94.9
Pennsylvania[b]	39,800	1.8	38,400–41,300	35,333	88.7	1.8	85.6–92.0
Puerto Rico[b]	17,300	3.2	16,200–18,400	15,520	89.8	3.2	84.6–95.8
Rhode Island	2,800	6.1	2,500–3,200	2,549	89.5	5.7	79.9–100
South Carolina	20,300	2.5	19,300–21,300	16,902	83.2	2.5	79.3–87.5
South Dakota	780	12.7	600–980	603	77.0	12.7	61.7–100
Tennessee	19,900	2.4	18,900–20,800	17,058	85.8	2.4	81.9–90.1
Texas	109,600	1.0	107,400–111,900	90,938	82.9	1.0	81.3–84.7
Utah	3,400	5.6	3,100–3,800	2,901	84.3	5.7	75.9–94.7
Vermont[b,c]	780	10.7	700–940	698	89.5	7.4	74.0–100
Virginia	26,200	2.1	25,100–27,300	22,673	86.6	2.1	83.1–90.3
Washington	15,400	2.7	14,600–16,200	13,421	87.2	2.7	82.9–92.1
West Virginia	2,300	7.2	1,900–2,600	1,871	82.7	7.3	72.5–96.3
Wisconsin	7,200	3.9	6,600–7,700	6,205	86.8	3.9	80.6–93.9
Wyoming	390	15.9	340–510	339	86.6	10.0	66.0–100

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—United States and Puerto Rico *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2019						
Alabama	16,500	2.9	15,600–17,400	13,767	83.4	2.9	79.0–88.4
Alaska	830	12.1	720–1,000	715	85.7	9.1	69.3–100
Arizona	20,500	2.5	19,500–21,500	17,132	83.5	2.5	79.6–87.8
Arkansas	7,200	4.3	6,600–7,800	5,892	81.5	4.4	75.1–89.1
California	150,900	0.9	148,100–153,600	132,146	87.6	0.9	86.0–89.2
Colorado	14,900	2.8	14,100–15,700	12,934	86.8	2.8	82.3–91.9
Connecticut	11,400	3.3	10,700–12,200	10,412	91.1	3.3	85.5–97.4
Delaware	3,700	5.7	3,300–4,200	3,332	89.2	5.7	80.2–100
District of Columbia	14,800	2.9	14,000–15,600	13,913	94.0	2.9	88.9–99.7
Florida	129,500	1.0	127,000–132,100	112,046	86.5	1.0	84.8–88.2
Georgia	66,900	1.4	65,100–68,700	55,933	83.6	1.4	81.5–85.9
Hawaii	2,700	7.1	2,400–3,100	2,369	87.8	6.7	77.1–100
Idaho[b]	1,500	10.8	1,200–1,800	1,213	82.3	9.9	67.9–100
Illinois	41,000	1.8	39,600–42,500	35,504	86.5	1.8	83.6–89.7
Indiana	13,900	3.1	13,100–14,800	11,507	82.6	3.2	77.8–88.1
Iowa	3,400	5.9	3,000–3,800	2,852	83.5	6.0	74.8–94.5
Kansas[b,c]	3,800	6.2	3,400–4,300	3,140	82.0	6.3	73.1–93.3
Kentucky[b]	9,100	3.6	8,500–9,800	7,570	83.2	3.7	77.6–89.6
Louisiana	25,500	2.4	24,300–26,700	21,117	82.9	2.4	79.1–86.9
Maine	1,800	8.0	1,600–2,100	1,629	89.2	6.6	77.0–100
Maryland	36,700	1.8	35,400–38,100	32,863	89.4	1.9	86.3–92.8
Massachusetts[c]	23,100	2.2	22,100–24,100	20,734	89.7	2.2	85.9–93.8
Michigan	19,500	2.7	18,400–20,500	16,390	84.2	2.7	80.0–88.9
Minnesota	9,900	3.3	9,300–10,600	8,695	87.8	3.3	82.4–93.9
Mississippi[c]	12,100	3.8	11,200–13,000	9,712	80.3	3.8	74.7–86.7
Missouri	14,500	2.9	13,700–15,400	12,703	87.3	2.9	82.6–92.6
Montana	750	11.1	670–920	666	88.5	7.9	72.7–100
Nebraska	2,600	6.9	2,200–2,900	2,204	85.1	7.0	75.0–98.3
Nevada[c]	13,200	3.2	12,400–14,000	10,650	80.6	3.2	75.8–86.0
New Hampshire	1,400	8.6	1,300–1,600	1,283	91.9	5.9	78.6–100
New Jersey[b]	39,200	2.1	37,600–40,700	34,555	88.2	2.1	84.8–92.0
New Mexico	4,300	5.0	3,900–4,700	3,710	86.2	5.1	78.5–95.7
New York	133,900	1.0	131,300–136,400	124,048	92.7	1.0	90.9–94.5
North Carolina	37,200	1.7	35,900–38,500	32,646	87.8	1.7	84.9–90.9
North Dakota[c]	750	18.5	480–1,000	484	64.1	21.1	47.1–100
Ohio	27,100	2.2	25,900–28,200	22,963	84.8	2.2	81.3–88.5
Oklahoma	7,600	4.3	7,000–8,300	6,299	82.7	4.4	76.2–90.4
Oregon	8,200	3.7	7,600–8,700	7,227	88.6	3.7	82.6–95.4
Pennsylvania[b]	40,200	1.9	38,700–41,700	35,897	89.3	1.9	86.1–92.7
Puerto Rico[b]	17,300	3.2	16,200–18,300	15,595	90.4	3.2	85.0–96.5
Rhode Island	2,900	6.2	2,600–3,300	2,605	89.8	5.7	80.0–100
South Carolina	20,800	2.6	19,800–21,900	17,393	83.5	2.6	79.4–88.0
South Dakota	810	13.0	640–1,000	638	78.6	12.1	62.6–100
Tennessee	20,200	2.5	19,300–21,200	17,491	86.4	2.5	82.4–90.8
Texas	113,300	1.1	111,000–115,700	94,449	83.3	1.1	81.6–85.1
Utah	3,600	5.7	3,200–4,000	3,051	84.6	5.8	76.0–95.3
Vermont[b,c]	790	11.0	710–960	710	89.6	7.5	73.7–100
Virginia	26,900	2.2	25,700–28,000	23,413	87.2	2.2	83.6–91.0
Washington	15,900	2.8	15,000–16,700	13,866	87.3	2.8	82.8–92.3
West Virginia	2,400	7.6	2,100–2,800	1,967	81.2	7.8	70.6–95.4
Wisconsin	7,400	4.0	6,800–7,900	6,421	87.2	4.0	80.9–94.5
Wyoming	380	16.9	340–510	335	87.4	10.0	65.6–100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Reported to the National HIV Surveillance System.

[b] Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[c] Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2017						
Arizona							
Maricopa County	13,000	2.9	12,200–13,700	10,775	83.2	2.9	78.7–88.1
California							
Alameda County	6,700	4.1	6,200–7,300	5,847	86.8	4.1	80.4–94.5
Los Angeles County	54,000	1.4	52,500–55,500	47,867	88.6	1.4	86.2–91.2
Orange County	8,100	3.8	7,500–8,700	6,742	83.3	3.8	77.5–89.9
Riverside County	9,500	2.7	9,000–10,000	8,507	89.3	2.7	84.7–94.3
Sacramento County	4,900	4.5	4,400–5,300	4,159	85.3	4.6	78.3–93.7
San Bernardino County	5,100	4.6	4,700–5,600	4,088	79.9	4.6	73.3–87.8
San Diego County	15,100	2.6	14,300–15,900	12,889	85.3	2.7	81.1–90.0
San Francisco County	13,000	3.4	12,300–13,900	12,304	94.8	3.0	88.8–100
District of Columbia	15,100	2.8	14,300–15,900	14,066	93.3	2.8	88.5–98.7
Florida							
Broward County	21,600	2.2	20,600–22,500	19,006	88.1	2.2	84.5–92.1
Duval County	7,100	4.0	6,500–7,700	5,839	82.2	4.0	76.2–89.3
Hillsborough County	7,800	3.8	7,200–8,400	6,581	84.6	3.8	78.7–91.5
Miami-Dade County	29,800	2.1	28,600–31,000	25,691	86.3	2.1	82.9–90.0
Orange County	9,900	3.3	9,300–10,600	8,280	83.4	3.4	78.3–89.3
Palm Beach County	8,900	3.7	8,200–9,500	7,733	87.0	3.7	81.2–93.9
Pinellas County	5,200	4.4	4,700–5,600	4,454	86.3	4.5	79.4–94.6
Georgia							
Cobb County	3,600	4.9	3,300–4,000	2,999	82.9	5.0	75.5–91.8
DeKalb County	9,600	3.3	9,000–10,300	8,154	84.6	3.3	79.5–90.5
Fulton County	16,800	2.5	16,000–17,600	14,302	85.1	2.5	81.2–89.5
Gwinnett County	3,300	4.8	3,000–3,700	2,736	81.8	4.8	74.8–90.3
Illinois							
Cook County	28,700	2.1	27,600–29,900	24,745	86.1	2.1	82.8–89.8
Indiana							
Marion County	5,300	4.4	4,900–5,800	4,494	84.5	4.5	77.7–92.5
Louisiana							
East Baton Rouge Parish	4,500	5.0	4,000–4,900	3,794	84.7	5.1	77.0–93.9
Orleans Parish	5,500	5.1	4,900–6,000	4,767	87.4	5.2	79.4–97.2
Maryland							
Baltimore City	12,000	3.4	11,200–12,700	10,869	90.9	3.4	85.3–97.4
Montgomery County	4,300	5.0	3,900–4,700	3,772	87.9	5.1	80.0–97.4
Prince George's County	8,800	3.4	8,200–9,400	7,529	85.6	3.4	80.2–91.7
Massachusetts							
Suffolk County[b]	6,300	4.3	5,700–6,800	5,702	91.2	4.3	84.1–99.6
Michigan							
Wayne County	7,500	4.3	6,900–8,200	6,370	84.4	4.3	77.9–92.1
Nevada							
Clark County[b]	9,900	3.2	9,300–10,600	7,982	80.4	3.2	75.6–85.9
New Jersey							
Essex County[c]	10,000	4.0	9,200–10,800	8,944	89.7	4.0	83.2–97.3
Hudson County[c]	5,500	5.2	4,900–6,100	4,797	87.0	5.3	78.9–96.9

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2017 *(cont)*						
New York							
Bronx County	28,400	1.8	27,400–29,400	26,604	93.7	1.8	90.4–97.1
Kings County	27,800	2.0	26,700–29,000	25,708	92.3	2.1	88.7–96.2
New York County	28,600	2.1	27,400–29,800	26,747	93.6	2.2	89.8–97.7
Queens County	17,000	2.6	16,100–17,800	15,384	90.6	2.6	86.3–95.4
North Carolina							
Mecklenburg County	6,500	3.9	6,000–7,000	5,623	86.8	3.9	80.6–94.0
Ohio							
Cuyahoga County	5,400	4.4	4,900–5,900	4,585	84.7	4.5	77.9–92.7
Franklin County	5,600	4.3	5,100–6,100	4,742	84.8	4.4	78.2–92.6
Hamilton County	3,600	5.5	3,200–4,000	2,875	79.7	5.5	72.0–89.3
Pennsylvania							
Philadelphia County	18,300	2.4	17,500–19,200	16,805	91.6	2.4	87.5–96.2
Puerto Rico							
San Juan Municipio[c]	3,600	7.4	3,200–4,100	3,206	88.9	6.4	77.6–100
Tennessee							
Shelby County	7,000	4.1	6,500–7,600	6,019	85.5	4.1	79.1–93.0
Texas							
Bexar County	7,400	3.8	6,800–7,900	6,084	82.4	3.9	76.7–89.2
Dallas County	20,700	2.3	19,700–21,600	17,306	83.7	2.3	80.1–87.7
Harris County	29,700	2.0	28,500–30,800	24,655	83.1	2.0	80.0–86.5
Tarrant County	6,500	4.0	6,000–7,100	5,425	82.9	4.0	76.9–89.9
Travis County	5,700	4.4	5,200–6,200	4,712	82.5	4.4	75.9–90.2
Washington							
King County	7,700	3.8	7,200–8,300	6,764	87.3	3.9	81.2–94.4

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2018						
Arizona							
Maricopa County	13,400	2.9	12,600–14,200	11,195	83.5	2.9	78.9–88.6
California							
Alameda County	6,900	4.1	6,300–7,400	6,008	87.4	4.2	80.8–95.1
Los Angeles County	54,600	1.5	53,000–56,100	48,674	89.2	1.5	86.7–91.9
Orange County	8,200	3.9	7,600–8,800	6,845	83.7	3.9	77.8–90.6
Riverside County	10,100	2.7	9,500–10,600	9,041	89.7	2.7	85.2–94.8
Sacramento County	5,000	4.6	4,500–5,400	4,263	85.6	4.7	78.5–94.1
San Bernardino County	5,400	4.6	4,900–5,900	4,422	81.4	4.6	74.7–89.4
San Diego County	15,300	2.7	14,500–16,100	13,075	85.3	2.7	81.0–90.0
San Francisco County	12,700	3.6	12,100–13,600	12,115	95.3	2.9	89.1–100
District of Columbia	14,900	2.8	14,100–15,700	13,940	93.6	2.9	88.7–99.1
Florida							
Broward County	21,800	2.2	20,800–22,700	19,274	88.5	2.2	84.8–92.6
Duval County	7,200	4.1	6,700–7,800	6,018	83.2	4.1	77.0–90.4
Hillsborough County	7,900	3.9	7,300–8,500	6,728	85.2	3.9	79.1–92.2
Miami-Dade County	30,100	2.1	28,800–31,300	26,015	86.5	2.1	83.1–90.3
Orange County	10,200	3.4	9,500–10,900	8,551	84.0	3.4	78.7–90.0
Palm Beach County	8,900	3.8	8,200–9,600	7,790	87.4	3.8	81.4–94.5
Pinellas County	5,100	4.6	4,700–5,600	4,482	87.1	4.6	79.9–95.7
Georgia							
Cobb County	3,800	5.1	3,400–4,100	3,144	83.5	5.1	75.9–92.7
DeKalb County	10,000	3.3	9,300–10,600	8,456	84.8	3.4	79.6–90.8
Fulton County	17,600	2.5	16,700–18,500	15,072	85.7	2.5	81.7–90.1
Gwinnett County	3,500	5.0	3,100–3,800	2,852	82.6	5.1	75.2–91.6
Illinois							
Cook County	28,900	2.1	27,700–30,100	25,050	86.6	2.1	83.1–90.3
Indiana							
Marion County	5,500	4.5	5,000–6,000	4,618	84.1	4.6	77.2–92.3
Louisiana							
East Baton Rouge Parish	4,600	5.2	4,100–5,000	3,857	84.5	5.2	76.7–94.1
Orleans Parish	5,500	5.2	5,000–6,100	4,859	87.9	5.3	79.7–97.9
Maryland							
Baltimore City	11,100	3.7	10,300–11,900	10,073	90.5	3.7	84.3–97.5
Montgomery County	4,300	5.1	3,900–4,700	3,822	88.7	5.2	80.6–98.6
Prince George's County	9,000	3.5	8,400–9,600	7,797	86.4	3.5	80.9–92.7
Massachusetts							
Suffolk County[b]	6,200	4.4	5,700–6,700	5,654	91.2	4.5	83.9–99.9
Michigan							
Wayne County	7,800	4.3	7,200–8,500	6,676	85.3	4.3	78.7–93.1
Nevada							
Clark County[b]	10,600	3.3	9,900–11,300	8,522	80.6	3.3	75.7–86.2
New Jersey							
Essex County[c]	9,900	4.1	9,100–10,700	8,914	90.0	4.1	83.2–97.8
Hudson County[c]	5,500	5.4	5,000–6,100	4,807	86.8	5.4	78.5–97.0

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2018 *(cont)*						
New York							
Bronx County	28,600	1.8	27,500–29,600	26,805	93.8	1.8	90.6–97.3
Kings County	27,900	2.1	26,800–29,100	25,888	92.6	2.1	89.0–96.6
New York County	28,500	2.2	27,300–29,700	26,738	93.9	2.2	90.1–98.1
Queens County	17,100	2.6	16,200–17,900	15,600	91.3	2.6	86.9–96.2
North Carolina							
Mecklenburg County	6,600	4.0	6,100–7,100	5,815	87.9	4.0	81.5–95.3
Ohio							
Cuyahoga County	5,500	4.5	5,000–6,000	4,684	85.5	4.5	78.6–93.8
Franklin County	5,700	4.5	5,200–6,200	4,803	84.7	4.5	77.8–92.8
Hamilton County	3,600	5.8	3,200–4,000	2,906	80.6	5.9	72.4–91.0
Pennsylvania							
Philadelphia County	18,200	2.5	17,400–19,100	16,757	91.8	2.5	87.6–96.5
Puerto Rico							
San Juan Municipio[c]	3,600	7.5	3,200–4,100	3,247	90.0	6.1	78.5–100
Tennessee							
Shelby County	7,200	4.1	6,600–7,800	6,273	86.8	4.1	80.3–94.4
Texas							
Bexar County	7,600	4.0	7,000–8,200	6,268	82.7	4.0	76.8–89.7
Dallas County	21,400	2.3	20,400–22,400	17,992	84.1	2.3	80.5–88.2
Harris County	30,500	2.0	29,200–31,700	25,469	83.6	2.0	80.5–87.1
Tarrant County	6,800	4.1	6,200–7,300	5,647	83.5	4.1	77.4–90.7
Travis County	5,900	4.4	5,400–6,500	4,892	82.2	4.5	75.6–90.1
Washington							
King County	7,800	4.0	7,200–8,400	6,828	87.4	4.0	81.1–94.8

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2019						
Arizona							
Maricopa County	13,900	3.0	13,100–14,700	11,691	84.0	3.0	79.3–89.3
California							
Alameda County	6,900	4.3	6,300–7,500	6,058	87.7	4.3	80.9–95.8
Los Angeles County	55,100	1.5	53,500–56,700	49,404	89.6	1.5	87.1–92.4
Orange County	8,200	4.0	7,600–8,900	6,941	84.3	4.0	78.2–91.4
Riverside County	10,400	2.8	9,900–11,000	9,414	90.2	2.8	85.5–95.4
Sacramento County	5,100	4.8	4,600–5,500	4,336	85.7	4.8	78.4–94.5
San Bernardino County	5,700	4.7	5,200–6,200	4,690	82.1	4.8	75.2–90.5
San Diego County	15,400	2.8	14,600–16,300	13,173	85.4	2.8	81.0–90.4
San Francisco County	12,500	3.7	12,000–13,400	11,992	95.9	2.8	89.5–100
District of Columbia	14,800	2.9	14,000–15,600	13,913	94.0	2.9	88.9–99.7
Florida							
Broward County	22,100	2.3	21,100–23,100	19,594	88.8	2.3	85.0–93.0
Duval County	7,300	4.2	6,700–7,900	6,159	84.4	4.2	78.0–92.0
Hillsborough County	8,100	3.9	7,400–8,700	6,948	86.1	4.0	80.0–93.4
Miami-Dade County	30,300	2.2	29,000–31,600	26,296	86.8	2.2	83.2–90.7
Orange County	10,400	3.5	9,700–11,100	8,770	84.4	3.6	78.9–90.7
Palm Beach County	9,000	3.9	8,300–9,700	7,890	87.6	3.9	81.5–94.8
Pinellas County	5,300	4.6	4,800–5,800	4,666	88.1	4.7	80.7–97.0
Georgia							
Cobb County	4,000	5.3	3,600–4,400	3,314	83.4	5.4	75.5–93.1
DeKalb County	10,300	3.4	9,600–11,000	8,815	85.5	3.4	80.2–91.6
Fulton County	18,100	2.5	17,200–19,000	15,584	86.2	2.6	82.1–90.8
Gwinnett County	3,600	5.4	3,200–4,000	3,033	83.6	5.4	75.6–93.4
Illinois							
Cook County	29,500	2.2	28,200–30,800	25,619	86.9	2.2	83.3–90.7
Indiana							
Marion County	5,500	4.8	5,000–6,000	4,610	83.5	4.9	76.2–92.3
Louisiana							
East Baton Rouge Parish	4,600	5.4	4,100–5,100	3,898	84.2	5.4	76.2–94.1
Orleans Parish	5,600	5.3	5,000–6,200	4,957	88.3	5.3	80.1–98.5
Maryland							
Baltimore City	11,100	3.8	10,300–11,900	10,109	91.0	3.8	84.7–98.2
Montgomery County	4,300	5.3	3,900–4,800	3,867	89.7	5.3	81.3–100
Prince George's County	9,100	3.6	8,500–9,800	7,947	86.9	3.6	81.3–93.5
Massachusetts							
Suffolk County[b]	6,200	4.5	5,700–6,800	5,695	91.2	4.5	83.8–100
Michigan							
Wayne County	8,000	4.3	7,400–8,700	6,889	85.6	4.4	78.9–93.5
Nevada							
Clark County[b]	11,200	3.5	10,400–12,000	8,976	80.1	3.5	74.9–85.9
New Jersey							
Essex County[c]	9,900	4.2	9,100–10,700	8,937	90.2	4.3	83.3–98.3
Hudson County[c]	5,600	5.5	5,000–6,200	4,845	87.3	5.6	78.7–97.8

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2019—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No.[a]	%	RSE (%)	95% CI
	2019 *(cont)*						
New York							
Bronx County	29,000	1.9	27,900–30,000	27,307	94.3	1.9	91.0–97.8
Kings County	27,900	2.1	26,800–29,100	25,949	93.0	2.1	89.2–97.0
New York County	28,300	2.2	27,100–29,500	26,649	94.1	2.2	90.2–98.4
Queens County	17,200	2.6	16,300–18,100	15,836	92.2	2.6	87.7–97.2
North Carolina							
Mecklenburg County	6,800	4.1	6,300–7,300	6,045	88.8	4.1	82.3–96.5
Ohio							
Cuyahoga County	5,500	4.6	5,000–6,000	4,758	86.2	4.7	79.0–94.9
Franklin County	5,900	4.6	5,400–6,400	5,013	85.2	4.6	78.2–93.6
Hamilton County	3,700	6.0	3,300–4,100	3,037	82.4	6.0	73.8–93.3
Pennsylvania							
Philadelphia County	18,400	2.5	17,500–19,300	16,951	92.2	2.5	87.8–97.0
Puerto Rico							
San Juan Municipio[c]	3,600	7.5	3,300–4,200	3,309	90.8	5.9	79.1–100
Tennessee							
Shelby County	7,200	4.3	6,600–7,800	6,256	87.2	4.3	80.4–95.1
Texas							
Bexar County	7,900	4.1	7,300–8,500	6,538	82.9	4.1	76.7–90.2
Dallas County	21,900	2.4	20,900–22,900	18,648	85.1	2.4	81.3–89.3
Harris County	27,300	2.4	26,000–28,500	22,267	81.6	2.4	78.0–85.7
Tarrant County	7,100	4.2	6,500–7,600	5,909	83.8	4.2	77.4–91.3
Travis County	6,100	4.5	5,600–6,600	5,028	82.5	4.6	75.7–90.5
Washington							
King County	8,000	4.1	7,400–8,600	7,015	87.7	4.1	81.2–95.4

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Data for the year 2019 are preliminary and based on deaths reported to CDC as of December 2020.

Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.

Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (…).

[a] Reported to the National HIV Surveillance System.

[b] Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

[c] Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: New Jersey. Areas with incomplete reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2020—United States

	2017	2018	2019	2020 *(preliminary)*[a]
	No.	No.	No.	No.
Gender				
Male	30,411	29,699	28,781	19,956
Female	7,248	7,025	6,868	4,517
Transgender male-to-female[b]	581	596	623	439
Transgender female-to-male[b]	36	48	46	38
Additional gender identity[c]	13	14	19	10
Age at diagnosis (yr)				
13–24	8,281	7,835	7,588	4,970
25–34	13,361	13,382	13,014	9,140
35–44	7,241	7,181	7,068	4,881
45–54	5,569	5,233	4,866	3,308
≥55	3,837	3,751	3,801	2,661
Race/ethnicity				
American Indian/Alaska Native	206	182	209	163
Asian	915	849	732	513
Black/African American	15,931	15,441	15,299	10,983
Hispanic/Latino[d]	10,460	10,530	10,112	6,135
Native Hawaiian/other Pacific Islander	51	64	66	57
White	9,546	9,293	9,006	6,642
Multiracial	1,180	1,023	913	467
Transmission category[e]				
Male-to-male sexual contact	25,337	24,556	23,866	16,964
Injection drug use				
Male	1,301	1,407	1,375	963
Female	1,053	1,084	1,106	674
Male-to-male sexual contact and injection drug use	1,421	1,408	1,457	833
Heterosexual contact[f]				
Male	2,913	2,903	2,685	1,620
Female	6,198	5,958	5,787	3,860
Other[g]				
Male	34	35	37	25
Female	33	32	25	21
Region of residence[h]				
Northeast	6,000	5,562	5,268	3,356
Midwest	5,086	4,932	4,750	3,417
South	19,658	19,364	19,100	13,291
West	7,545	7,524	7,219	4,896
Total	**38,289**	**37,382**	**36,337**	**24,960**

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

[b] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[c] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[d] Hispanic/Latino persons can be of any race.

[e] Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[f] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[g] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[h] Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2020— United States and 6 dependent areas

	2017	2018	2019	2020 (preliminary)[a]
	No.	No.	No.	No.
Gender				
Male	30,780	30,066	29,101	20,169
Female	7,342	7,106	6,949	4,554
Transgender male-to-female[b]	583	597	625	440
Transgender female-to-male[b]	36	48	46	38
Additional gender identity[c]	13	14	19	10
Age at diagnosis (yr)				
13–24	8,359	7,909	7,648	5,015
25–34	13,490	13,517	13,127	9,209
35–44	7,331	7,259	7,147	4,932
45–54	5,662	5,327	4,931	3,349
≥55	3,912	3,819	3,887	2,706
Race/ethnicity				
American Indian/Alaska Native	206	182	209	163
Asian	918	853	738	513
Black/African American	15,935	15,448	15,305	10,985
Hispanic/Latino[d]	10,910	10,960	10,494	6,382
Native Hawaiian/other Pacific Islander	54	66	70	57
White	9,550	9,297	9,011	6,644
Multiracial	1,181	1,025	913	467
Transmission category[e]				
Male-to-male sexual contact	25,580	24,819	24,084	17,118
Injection drug use				
Male	1,333	1,432	1,397	985
Female	1,062	1,086	1,111	676
Male-to-male sexual contact and injection drug use	1,432	1,420	1,468	839
Heterosexual contact[f]				
Male	2,997	2,970	2,754	1,653
Female	6,283	6,037	5,863	3,894
Other[g]				
Male	34	35	37	25
Female	33	32	25	21
Region of residence[h]				
Northeast	6,000	5,562	5,268	3,356
Midwest	5,086	4,932	4,750	3,417
South	19,658	19,364	19,100	13,291
West	7,545	7,524	7,219	4,896
U.S. dependent areas	465	449	403	251
Total	**38,754**	**37,831**	**36,740**	**25,211**

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

[b] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[c] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[d] Hispanic/Latino persons can be of any race.

[e] Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[f] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[g] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[h] Data are based on residence at time of diagnosis of HIV infection.

Table 3c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2020— United States and 6 dependent areas

Area of residence	2017 No.	2018 No.	2019 No.	2020 *(preliminary)*[a] No.
Alabama	650	607	638	514
Alaska	29	23	27	29
Arizona	727	753	761	605
Arkansas	287	278	287	253
California	4,806	4,715	4,354	2,828
Colorado	435	402	461	295
Connecticut	274	259	213	147
Delaware	126	91	93	94
District of Columbia	316	281	255	184
Florida	4,557	4,530	4,378	3,468
Georgia	2,596	2,482	2,439	1,583
Hawaii	77	72	65	38
Idaho	46	37	28	9
Illinois	1,367	1,374	1,252	681
Indiana	515	509	486	398
Iowa	125	116	100	90
Kansas	119	157	131	103
Kentucky	365	378	326	242
Louisiana	996	961	881	729
Maine	29	30	30	16
Maryland	1,020	991	918	591
Massachusetts	608	649	535	305
Michigan	773	715	674	511
Minnesota	277	288	274	210
Mississippi	428	476	477	341
Missouri	502	449	488	348
Montana	32	23	25	14
Nebraska	88	79	81	56
Nevada	494	501	512	297
New Hampshire	32	38	31	29
New Jersey	1,123	1,021	1,057	525
New Mexico	141	135	156	51
New York	2,729	2,449	2,330	1,593
North Carolina	1,295	1,186	1,365	1,026
North Dakota	38	36	40	11
Ohio	983	973	980	789
Oklahoma	299	278	320	194
Oregon	203	230	199	169
Pennsylvania	1,100	1,023	989	687
Rhode Island	85	75	72	47
South Carolina	706	712	680	656
South Dakota	39	29	33	32
Tennessee	721	746	773	614
Texas	4,356	4,422	4,302	2,095
Utah	113	121	135	126
Vermont	20	18	11	7
Virginia	863	861	822	594
Washington	432	500	483	423
West Virginia	77	84	146	113
Wisconsin	260	207	211	188
Wyoming	10	12	13	12
Subtotal	38,289	37,382	36,337	24,960
U.S. dependent areas				
American Samoa	0	0	0	0
Guam	6	7	10	0
Northern Mariana Islands	1	1	2	0
Puerto Rico	450	431	383	249
Republic of Palau	0	0	0	0
U.S. Virgin Islands	8	10	8	2
Subtotal	465	449	403	251
Total	**38,754**	**37,831**	**36,740**	**25,211**

Note. Data are based on residence at time of diagnosis of HIV infection.

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 3d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2020—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	2017 No.	2018 No.	2019 No.	2020 *(preliminary)*[a] No.
Arizona				
Maricopa County	497	530	513	442
California				
Alameda County	203	199	219	137
Los Angeles County	1,725	1,685	1,482	931
Orange County	313	287	246	246
Riverside County	276	262	268	214
Sacramento County	170	156	136	20
San Bernardino County	254	263	287	179
San Diego County	414	382	366	196
San Francisco County	243	238	207	149
District of Columbia	316	281	255	184
Florida				
Broward County	671	616	594	479
Duval County	297	275	273	222
Hillsborough County	300	299	266	259
Miami-Dade County	1,145	1,168	1,151	826
Orange County	461	461	466	372
Palm Beach County	289	280	237	215
Pinellas County	163	175	184	151
Georgia				
Cobb County	156	153	179	112
DeKalb County	366	355	351	218
Fulton County	615	592	537	440
Gwinnett County	178	148	208	93
Illinois				
Cook County	979	983	881	531
Indiana				
Marion County	227	204	206	146
Louisiana				
East Baton Rouge Parish	163	177	153	119
Orleans Parish	184	179	158	104
Maryland				
Baltimore City	236	231	199	141
Montgomery County	164	126	132	73
Prince George's County	308	306	279	165
Massachusetts				
Suffolk County	165	149	133	99
Michigan				
Wayne County	323	300	285	218
Nevada				
Clark County	445	445	449	255
New Jersey				
Essex County	315	265	234	127
Hudson County	164	161	147	93

Table 3d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2020—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	2017 No.	2018 No.	2019 No.	2020 *(preliminary)*[a] No.
New York				
Bronx County	505	456	499	271
Kings County	628	547	466	348
New York County	394	374	338	247
Queens County	431	413	354	251
North Carolina				
Mecklenburg County	270	242	267	201
Ohio				
Cuyahoga County	148	149	162	171
Franklin County	222	194	214	171
Hamilton County	187	183	173	117
Pennsylvania				
Philadelphia County	506	439	446	278
Puerto Rico				
San Juan Municipio	112	106	85	57
Tennessee				
Shelby County	260	291	263	224
Texas				
Bexar County	349	325	336	216
Dallas County	813	794	733	526
Harris County	1,102	1,206	1,195	339
Tarrant County	304	277	307	185
Travis County	212	188	174	111
Washington				
King County	211	292	245	214

Note. Data are based on residence at time of diagnosis of HIV infection.

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2019–September 2020—44 states and the District of Columbia

		≥1 CD4 or VL tests		No CD4 or VL test	
	Total No.	No.	%	No.	%
			2019		
Gender					
Male	26,827	21,873	81.5	4,954	18.5
Female	6,322	5,067	80.1	1,255	19.9
Transgender male-to-female[a]	584	484	82.9	100	17.1
Transgender female-to-male[a]	45	40	88.9	5	11.1
Additional gender identity[b]	17	15	88.2	2	11.8
Age at diagnosis (yr)					
13–24	7,093	5,602	79.0	1,491	21.0
25–34	12,105	9,775	80.8	2,330	19.2
35–44	6,560	5,405	82.4	1,155	17.6
45–54	4,523	3,767	83.3	756	16.7
≥55	3,514	2,930	83.4	584	16.6
Race/ethnicity					
American Indian/Alaska Native	206	172	83.5	34	16.5
Asian	687	570	83.0	117	17.0
Black/African American	14,268	11,179	78.4	3,089	21.6
Hispanic/Latino[c]	9,478	8,004	84.4	1,474	15.6
Native Hawaiian/other Pacific Islander	66	53	80.3	13	19.7
White	8,249	6,817	82.6	1,432	17.4
Multiracial	841	684	81.3	157	18.7
Transmission category[d]					
Male-to-male sexual contact	22,392	18,389	82.1	4,003	17.9
Injection drug use	2,175	1,640	75.4	535	24.6
Male	1,190	900	75.7	290	24.3
Female	985	740	75.1	245	24.9
Male-to-male sexual contact and injection drug use	1,347	1,080	80.2	267	19.8
Heterosexual contact[e]	7,821	6,320	80.8	1,501	19.2
Male	2,459	1,969	80.1	490	19.9
Female	5,362	4,351	81.1	1,011	18.9
Total[f]	**33,795**	**27,479**	**81.3**	**6,316**	**18.7**

Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2019–September 2020—44 states and the District of Columbia *(cont)*

		≥1 CD4 or VL tests		No CD4 or VL test	
	Total No.	No.	%	No.	%
	2020 (January–September, *preliminary*)[g]				
Gender					
Male	15,460	12,774	82.6	2,686	17.4
Female	3,549	2,928	82.5	621	17.5
Transgender male-to-female[a]	349	292	83.7	57	16.3
Transgender female-to-male[a]	28	27	96.4	1	3.6
Additional gender identity[b]	7	7	100	0	0.0
Age at diagnosis (yr)					
13–24	3,895	3,133	80.4	762	19.6
25–34	7,160	5,896	82.3	1,264	17.7
35–44	3,719	3,067	82.5	652	17.5
45–54	2,542	2,167	85.2	375	14.8
≥55	2,077	1,765	85.0	312	15.0
Race/ethnicity					
American Indian/Alaska Native	127	103	81.1	24	18.9
Asian	409	366	89.5	43	10.5
Black/African American	8,510	6,870	80.7	1,640	19.3
Hispanic/Latino[c]	4,902	4,111	83.9	791	16.1
Native Hawaiian/other Pacific Islander	49	41	83.7	8	16.3
White	5,028	4,217	83.9	811	16.1
Multiracial	368	320	87.0	48	13.0
Transmission category[d]					
Male-to-male sexual contact	13,203	10,955	83.0	2,247	17.0
Injection drug use	1,232	985	80.0	246	20.0
Male	694	556	80.2	137	19.8
Female	538	429	79.7	109	20.3
Male-to-male sexual contact and injection drug use	650	531	81.7	119	18.3
Heterosexual contact[e]	4,271	3,523	82.5	749	17.5
Male	1,251	1,014	81.1	237	18.9
Female	3,020	2,509	83.1	512	16.9
Total[f]	**19,393**	**16,028**	**82.6**	**3,365**	**17.4**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified.

[g] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 4b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—44 states and the District of Columbia

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
		2019			
Alabama	638	505	79.2	133	20.8
Alaska	27	23	85.2	4	14.8
Arizona	761	630	82.8	131	17.2
Arkansas	287	229	79.8	58	20.2
California	4,354	3,601	82.7	753	17.3
Colorado	461	385	83.5	76	16.5
Connecticut	213	186	87.3	27	12.7
Delaware	93	71	76.3	22	23.7
District of Columbia	255	210	82.4	45	17.6
Florida	4,378	3,662	83.6	716	16.4
Georgia	2,439	1,961	80.4	478	19.6
Hawaii	65	55	84.6	10	15.4
Illinois	1,252	1,042	83.2	210	16.8
Indiana	486	307	63.2	179	36.8
Iowa	100	91	91.0	9	9.0
Louisiana	881	722	82.0	159	18.0
Maine	30	28	93.3	2	6.7
Maryland	918	798	86.9	120	13.1
Massachusetts	535	486	90.8	49	9.2
Michigan	674	565	83.8	109	16.2
Minnesota	274	250	91.2	24	8.8
Mississippi	477	339	71.1	138	28.9
Missouri	488	376	77.0	112	23.0
Montana	25	22	88.0	3	12.0
Nebraska	81	65	80.2	16	19.8
Nevada	512	425	83.0	87	17.0
New Hampshire	31	27	87.1	4	12.9
New Mexico	156	138	88.5	18	11.5
New York	2,330	2,027	87.0	303	13.0
North Carolina	1,365	1,077	78.9	288	21.1
North Dakota	40	36	90.0	4	10.0
Ohio	980	819	83.6	161	16.4
Oklahoma	320	222	69.4	98	30.6
Oregon	199	173	86.9	26	13.1
Rhode Island	72	65	90.3	7	9.7
South Carolina	680	596	87.6	84	12.4
South Dakota	33	26	78.8	7	21.2
Tennessee	773	534	69.1	239	30.9
Texas	4,302	3,210	74.6	1,092	25.4
Utah	135	106	78.5	29	21.5
Virginia	822	647	78.7	175	21.3
Washington	483	432	89.4	51	10.6
West Virginia	146	107	73.3	39	26.7
Wisconsin	211	190	90.0	21	10.0
Wyoming	13	13	100	0	0.0
Total	**33,795**	**27,479**	**81.3**	**6,316**	**18.7**

Table 4b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—44 states and the District of Columbia *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–September, *preliminary*)[a]				
Alabama	432	335	77.5	97	22.5
Alaska	24	23	95.8	1	4.2
Arizona	504	427	84.7	77	15.3
Arkansas	211	176	83.4	35	16.6
California	2,424	2,063	85.1	361	14.9
Colorado	232	201	86.6	31	13.4
Connecticut	133	111	83.5	22	16.5
Delaware	73	58	79.5	15	20.5
District of Columbia	144	130	90.3	14	9.7
Florida	2,677	2,258	84.3	419	15.7
Georgia	1,330	1,148	86.3	182	13.7
Hawaii	28	25	89.3	3	10.7
Illinois	621	532	85.7	89	14.3
Indiana	320	232	72.5	88	27.5
Iowa	70	63	90.0	7	10.0
Louisiana	543	408	75.1	135	24.9
Maine	13	12	92.3	1	7.7
Maryland	507	460	90.7	47	9.3
Massachusetts	276	240	87.0	36	13.0
Michigan	392	327	83.4	65	16.6
Minnesota	162	141	87.0	21	13.0
Mississippi	282	215	76.2	67	23.8
Missouri	273	213	78.0	60	22.0
Montana	8	7	87.5	1	12.5
Nebraska	44	41	93.2	3	6.8
Nevada	257	222	86.4	35	13.6
New Hampshire	22	17	77.3	5	22.7
New Mexico	47	41	87.2	6	12.8
New York	1,399	1,226	87.6	173	12.4
North Carolina	802	665	82.9	137	17.1
North Dakota	11	10	90.9	1	9.1
Ohio	690	607	88.0	83	12.0
Oklahoma	156	122	78.2	34	21.8
Oregon	131	113	86.3	18	13.7
Rhode Island	44	41	93.2	3	6.8
South Carolina	529	467	88.3	62	11.7
South Dakota	27	23	85.2	4	14.8
Tennessee	497	370	74.4	127	25.6
Texas	1,911	1,331	69.6	580	30.4
Utah	103	46	44.7	57	55.3
Virginia	474	380	80.2	94	19.8
Washington	319	287	90.0	32	10.0
West Virginia	101	78	77.2	23	22.8
Wisconsin	141	128	90.8	13	9.2
Wyoming	9	8	88.9	1	11.1
Total	19,393	16,028	82.6	3,365	17.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2019				
Arizona					
Maricopa County	513	417	81.3	96	18.7
California					
Alameda County	219	195	89.0	24	11.0
Los Angeles County	1,482	1,198	80.8	284	19.2
Orange County	246	199	80.9	47	19.1
Riverside County	268	216	80.6	52	19.4
Sacramento County	136	118	86.8	18	13.2
San Bernardino County	287	208	72.5	79	27.5
San Diego County	366	317	86.6	49	13.4
San Francisco County	207	199	96.1	8	3.9
District of Columbia	255	210	82.4	45	17.6
Florida					
Broward County	594	517	87.0	77	13.0
Duval County	273	210	76.9	63	23.1
Hillsborough County	266	228	85.7	38	14.3
Miami-Dade County	1,151	971	84.4	180	15.6
Orange County	466	365	78.3	101	21.7
Palm Beach County	237	187	78.9	50	21.1
Pinellas County	184	157	85.3	27	14.7
Georgia					
Cobb County	179	151	84.4	28	15.6
DeKalb County	351	284	80.9	67	19.1
Fulton County	537	450	83.8	87	16.2
Gwinnett County	208	170	81.7	38	18.3
Illinois					
Cook County	881	732	83.1	149	16.9
Indiana					
Marion County	206	108	52.4	98	47.6
Louisiana					
East Baton Rouge Parish	153	135	88.2	18	11.8
Orleans Parish	158	130	82.3	28	17.7
Maryland					
Baltimore City	199	169	84.9	30	15.1
Montgomery County	132	117	88.6	15	11.4
Prince George's County	279	245	87.8	34	12.2
Massachusetts					
Suffolk County	133	124	93.2	9	6.8
Michigan					
Wayne County	285	243	85.3	42	14.7
Nevada					
Clark County	449	371	82.6	78	17.4
New York					
Bronx County	499	435	87.2	64	12.8
Kings County	466	397	85.2	69	14.8
New York County	338	297	87.9	41	12.1
Queens County	354	302	85.3	52	14.7

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2019 *(cont)*				
North Carolina					
Mecklenburg County	267	209	78.3	58	21.7
Ohio					
Cuyahoga County	162	143	88.3	19	11.7
Franklin County	214	196	91.6	18	8.4
Hamilton County	173	147	85.0	26	15.0
Pennsylvania					
Philadelphia County	446	377	84.5	69	15.5
Tennessee					
Shelby County	263	160	60.8	103	39.2
Texas					
Bexar County	336	237	70.5	99	29.5
Dallas County	733	557	76.0	176	24.0
Harris County	1,195	889	74.4	306	25.6
Tarrant County	307	218	71.0	89	29.0
Travis County	174	152	87.4	22	12.6
Washington					
King County	245	222	90.6	23	9.4

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–September, *preliminary*)[a]				
Arizona					
Maricopa County	364	312	85.7	52	14.3
California					
Alameda County	117	98	83.8	19	16.2
Los Angeles County	806	688	85.4	118	14.6
Orange County	201	180	89.6	21	10.4
Riverside County	176	145	82.4	31	17.6
Sacramento County	15	11	73.3	4	26.7
San Bernardino County	166	123	74.1	43	25.9
San Diego County	191	170	89.0	21	11.0
San Francisco County	116	111	95.7	5	4.3
District of Columbia	144	130	90.3	14	9.7
Florida					
Broward County	359	310	86.4	49	13.6
Duval County	178	143	80.3	35	19.7
Hillsborough County	196	167	85.2	29	14.8
Miami-Dade County	641	533	83.2	108	16.8
Orange County	289	251	86.9	38	13.1
Palm Beach County	179	148	82.7	31	17.3
Pinellas County	116	101	87.1	15	12.9
Georgia					
Cobb County	87	78	89.7	9	10.3
DeKalb County	186	164	88.2	22	11.8
Fulton County	356	311	87.4	45	12.6
Gwinnett County	84	67	79.8	17	20.2
Illinois					
Cook County	479	410	85.6	69	14.4
Indiana					
Marion County	126	90	71.4	36	28.6
Louisiana					
East Baton Rouge Parish	95	75	78.9	20	21.1
Orleans Parish	72	57	79.2	15	20.8
Maryland					
Baltimore City	124	111	89.5	13	10.5
Montgomery County	60	57	95.0	3	5.0
Prince George's County	150	137	91.3	13	8.7
Massachusetts					
Suffolk County	85	74	87.1	11	12.9
Michigan					
Wayne County	168	138	82.1	30	17.9
Nevada					
Clark County	222	191	86.0	31	14.0
New York					
Bronx County	241	208	86.3	33	13.7
Kings County	306	265	86.6	41	13.4
New York County	214	179	83.6	35	16.4
Queens County	229	212	92.6	17	7.4

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis among persons aged ≥13 years, by area of residence, January 2019–September 2020—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–September, *preliminary*)[a] *(cont)*				
North Carolina					
Mecklenburg County	148	122	82.4	26	17.6
Ohio					
Cuyahoga County	141	131	92.9	10	7.1
Franklin County	153	137	89.5	16	10.5
Hamilton County	102	92	90.2	10	9.8
Pennsylvania					
Philadelphia County	223	193	86.5	30	13.5
Tennessee					
Shelby County	185	128	69.2	57	30.8
Texas					
Bexar County	208	132	63.5	76	36.5
Dallas County	462	319	69.0	143	31.0
Harris County	335	233	69.6	102	30.4
Tarrant County	158	103	65.2	55	34.8
Travis County	99	77	77.8	22	22.2
Washington					
King County	151	140	92.7	11	7.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

[a] Data are for cases reported to CDC through December 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 5a. HIV viral suppression during 2019 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by selected characteristics—44 states and the District of Columbia

	Persons alive at year-end 2019	VL <200 copies/mL	
	No.	No.	%
Gender			
Male	702,412	462,753	65.9
Female	212,405	136,113	64.1
Transgender male-to-female[a]	9,699	6,503	67.0
Transgender female-to-male[a]	391	267	68.3
Additional gender identity[b]	170	120	70.6
Age at year-end 2018 (yr)			
13–24	29,533	18,681	63.3
25–34	147,061	91,988	62.6
35–44	175,204	110,891	63.3
45–54	254,886	169,826	66.6
≥55	318,393	214,370	67.3
Race/ethnicity			
American Indian/Alaska Native	2,924	1,836	62.8
Asian[c]	13,903	9,731	70.0
Black/African American	371,711	225,899	60.8
Hispanic/Latino[d]	220,914	142,709	64.6
Native Hawaiian/other Pacific Islander	815	529	64.9
White	270,980	193,402	71.4
Multiracial	43,145	31,592	73.2
Transmission category[e]			
Male-to-male sexual contact	528,606	359,821	68.1
Injection drug use	98,291	55,907	56.9
Male	56,813	30,489	53.7
Female	41,478	25,418	61.3
Male-to-male sexual contact and injection drug use	51,307	33,657	65.6
Heterosexual contact[f]	233,548	148,842	63.7
Male	68,761	41,608	60.5
Female	164,787	107,234	65.1
Other[g]	13,325	7,529	56.5
Male	6,771	3,787	55.9
Female	6,554	3,742	57.1
Total[h]	**925,077**	**605,756**	**65.5**

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that lack laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Includes Asian/Pacific Islander legacy cases.

[d] Hispanic/Latino persons can be of any race.

[e] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

[f] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[g] Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified.

[h] Includes 685 persons of unknown race/ethnicity.

Table 5b. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence—44 states and the District of Columbia

Area of residence	Persons alive at year-end 2019	VL <200 copies/mL	
	No.	No.	%
Alabama	13,245	8,837	66.7
Alaska	700	552	78.9
Arizona	16,537	10,276	62.1
Arkansas	5,668	2,715	47.9
California	128,592	86,913	67.6
Colorado	12,556	7,526	59.9
Connecticut	10,380	7,059	68.0
Delaware	3,286	2,456	74.7
District of Columbia	13,777	8,082	58.7
Florida	109,195	73,187	67.0
Georgia	54,031	33,270	61.6
Hawaii	2,324	1,762	75.8
Illinois	34,564	19,097	55.3
Indiana	11,145	6,705	60.2
Iowa	2,785	2,275	81.7
Louisiana	20,425	13,952	68.3
Maine	1,613	1,307	81.0
Maryland	32,466	21,083	64.9
Massachusetts[a]	20,514	14,581	71.1
Michigan	15,903	11,713	73.7
Minnesota	8,532	5,934	69.5
Mississippi[a]	9,356	5,043	53.9
Missouri	12,320	8,277	67.2
Montana	638	535	83.9
Nebraska	2,151	1,355	63.0
Nevada[a]	10,228	5,911	57.8
New Hampshire	1,273	965	75.8
New Mexico	3,582	2,162	60.4
New York	124,135	81,751	65.9
North Carolina	31,640	21,291	67.3
North Dakota[a]	456	324	71.1
Ohio	22,204	13,969	62.9
Oklahoma	6,033	3,521	58.4
Oregon	7,080	5,701	80.5
Rhode Island	2,584	2,047	79.2
South Carolina	16,917	11,967	70.7
South Dakota	618	321	51.9
Tennessee	16,957	11,383	67.1
Texas	90,852	56,315	62.0
Utah	2,947	2,092	71.0
Virginia	22,870	14,462	63.2
Washington	13,539	10,861	80.2
West Virginia	1,847	1,182	64.0
Wisconsin	6,279	4,813	76.7
Wyoming	333	226	67.9

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete lab reporting: Kansas, Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[a] Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 5c. HIV viral suppression during 2019 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons alive at year-end 2019	VL <200 copies/mL	
	No.	No.	%
Arizona			
Maricopa County	11,288	7,262	64.3
California			
Alameda County	5,886	4,311	73.2
Los Angeles County	48,185	31,185	64.7
Orange County	6,744	4,438	65.8
Riverside County	9,196	7,198	78.3
Sacramento County	4,230	2,984	70.5
San Bernardino County	4,445	2,759	62.1
San Diego County	12,882	7,866	61.1
San Francisco County	11,804	9,086	77.0
District of Columbia	13,777	8,082	58.7
Florida			
Broward County	19,237	13,416	69.7
Duval County	5,973	3,816	63.9
Hillsborough County	6,784	4,891	72.1
Miami-Dade County	25,480	15,194	59.6
Orange County	8,432	5,815	69.0
Palm Beach County	7,785	4,854	62.4
Pinellas County	4,521	3,437	76.0
Georgia			
Cobb County	3,168	2,049	64.7
DeKalb County	8,528	5,504	64.5
Fulton County	15,116	9,378	62.0
Gwinnett County	2,885	1,921	66.6
Illinois			
Cook County	24,960	13,074	52.4
Indiana			
Marion County	4,450	2,611	58.7
Louisiana			
East Baton Rouge Parish	3,795	2,775	73.1
Orleans Parish	4,833	3,294	68.2
Maryland			
Baltimore City	10,091	6,409	63.5
Montgomery County	3,787	2,148	56.7
Prince George's County	7,786	5,063	65.0
Massachusetts			
Suffolk County[a]	5,621	3,986	70.9
Michigan			
Wayne County	6,666	4,652	69.8
Nevada			
Clark County[a]	8,601	5,068	58.9
New York			
Bronx County	27,548	18,158	65.9
Kings County	26,035	16,886	64.9
New York County	26,599	16,660	62.6
Queens County	15,730	10,124	64.4

Table 5c. HIV viral suppression during 2019 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons alive at year-end 2019	VL <200 copies/mL	
	No.	No.	%
North Carolina			
Mecklenburg County	5,822	4,068	69.9
Ohio			
Cuyahoga County	4,642	3,082	66.4
Franklin County	4,846	3,275	67.6
Hamilton County	2,884	1,406	48.8
Pennsylvania			
Philadelphia County	16,731	10,656	63.7
Tennessee			
Shelby County	6,079	3,957	65.1
Texas			
Bexar County	6,246	4,088	65.4
Dallas County	17,992	10,980	61.0
Harris County	21,455	12,282	57.2
Tarrant County	5,678	3,695	65.1
Travis County	4,873	3,662	75.1
Washington			
King County	6,844	5,673	82.9

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey. Areas with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.

[a] Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 6a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥16 years, by selected characteristics—United States

	Persons prescribed PrEP[a]	Persons with PrEP indications[b]	PrEP coverage[c]
	No.	No.	%
	2017		
Sex at birth			
Male	149,620	993,840	15.1
Female	11,458	227,240	5.0
Age (yr)			
16–24	20,071	259,130	7.7
25–34	64,906	425,690	15.2
35–44	38,088	233,560	16.3
45–54	25,252	180,870	14.0
≥55	12,868	121,830	10.6
Race/ethnicity[d]			
Black/African American	20,255	475,100	4.3
Hispanic/Latino[e]	23,142	299,580	7.7
Other	7,149	132,040	5.4
White	110,638	311,250	35.5
Total	**161,185**	**1,221,080**	**13.2**
	2018		
Sex at birth			
Male	210,427	989,200	21.3
Female	15,995	227,010	7.0
Age (yr)			
16–24	29,743	246,290	12.1
25–34	92,924	434,680	21.4
35–44	52,576	238,470	22.0
45–54	32,775	173,420	18.9
≥55	18,523	123,350	15.0
Race/ethnicity[d]			
Black/African American	29,262	468,540	6.2
Hispanic/Latino[e]	34,228	312,820	10.9
Other	9,836	131,180	7.5
White	153,215	300,650	51.0
Total	**226,541**	**1,216,210**	**18.6**
	2019		
Sex at birth			
Male	262,360	989,200	26.5
Female	21,955	227,010	9.7
Age (yr)			
16–24	38,316	246,290	15.6
25–34	116,012	434,680	26.7
35–44	66,005	238,470	27.7
45–54	38,718	173,420	22.3
≥55	25,413	123,350	20.6
Race/ethnicity[d]			
Black/African American	38,284	468,540	8.2
Hispanic/Latino[e]	43,812	312,820	14.0
Other	11,953	131,180	9.1
White	190,415	300,650	63.3
Total	**284,464**	**1,216,210**	**23.4**

Table 6a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥16 years, by selected characteristics—United States *(cont)*

	Persons prescribed PrEP[a]	Persons with PrEP indications[b]	PrEP coverage[c]
	No.	No.	%
	2020 (January–September)		
Sex at birth			
Male	254,738	989,200	25.8
Female	20,430	227,010	9.0
Age (yr)			
16–24	31,871	246,290	12.9
25–34	108,718	434,680	25.0
35–44	67,169	238,470	28.2
45–54	38,505	173,420	22.2
≥55	29,006	123,350	23.5
Race/ethnicity[d]			
Black/African American	37,467	468,540	8.0
Hispanic/Latino[e]	42,831	312,820	13.7
Other	11,201	131,180	8.5
White	183,769	300,650	61.1
Total	**275,269**	**1,216,210**	**22.6**

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

[a] Estimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

[e] Hispanic/Latino persons can be of any race.

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2017	
Alabama	1,014	11,390	8.9
Alaska	120	2,370	5.1
Arizona	2,430	26,820	9.1
Arkansas	445	4,840	9.2
California	28,138	166,150	16.9
Colorado	2,484	25,510	9.7
Connecticut	1,636	10,970	14.9
Delaware	287	4,860	5.9
District of Columbia	4,018	13,710	29.3
Florida	8,731	125,160	7.0
Georgia	4,685	40,680	11.5
Hawaii	460	5,440	8.5
Idaho	272	3,860	7.0
Illinois	10,605	54,620	19.4
Indiana	1,577	21,640	7.3
Iowa	803	4,280	18.8
Kansas	556	5,570	10.0
Kentucky	781	13,170	5.9
Louisiana	2,458	15,490	15.9
Maine	318	3,270	9.7
Maryland	2,815	28,150	10.0
Massachusetts	5,996	25,110	23.9
Michigan	2,307	28,520	8.1
Minnesota	2,581	23,770	10.9
Mississippi	465	5,030	9.2
Missouri	1,983	19,420	10.2
Montana	123	2,750	4.5
Nebraska	361	2,590	13.9
Nevada	1,127	10,870	10.4
New Hampshire	338	3,110	10.9
New Jersey	3,457	28,590	12.1
New Mexico	618	6,720	9.2
New York	23,455	74,450	31.5
North Carolina	2,736	33,110	8.3
North Dakota	111	1,230	9.0
Ohio	3,645	40,940	8.9
Oklahoma	555	11,030	5.0
Oregon	2,073	20,720	10.0
Pennsylvania	6,326	36,160	17.5
Puerto Rico[d]	120	9,700	1.2
Rhode Island	657	4,360	15.1
South Carolina	720	10,390	6.9
South Dakota	60	1,000	6.0
Tennessee	1,802	22,890	7.9
Texas	11,750	123,400	9.5
Utah	1,045	6,900	15.1
Vermont	216	1,490	14.5
Virginia	2,167	33,670	6.4
Washington	6,952	35,600	19.5
West Virginia	242	3,660	6.6
Wisconsin	1,428	14,230	10.0
Wyoming	50	1,410	3.5

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2018	
Alabama	1,557	11,020	14.1
Alaska	196	1,780	11.0
Arizona	3,694	25,780	14.3
Arkansas	632	5,130	12.3
California	37,659	165,030	22.8
Colorado	3,517	25,120	14.0
Connecticut	2,349	9,560	24.6
Delaware	423	4,400	9.6
District of Columbia	5,212	12,950	40.2
Florida	14,999	125,330	12.0
Georgia	6,548	39,030	16.8
Hawaii	698	4,360	16.0
Idaho	380	4,790	7.9
Illinois	14,334	55,860	25.7
Indiana	2,251	22,170	10.2
Iowa	1,186	4,760	24.9
Kansas	751	5,060	14.8
Kentucky	1,244	12,990	9.6
Louisiana	3,574	15,920	22.4
Maine	494	3,950	12.5
Maryland	4,089	27,300	15.0
Massachusetts	8,191	24,900	32.9
Michigan	3,544	29,570	12.0
Minnesota	3,552	21,720	16.4
Mississippi	655	4,530	14.5
Missouri	2,850	18,370	15.5
Montana	185	2,290	8.1
Nebraska	481	2,180	22.1
Nevada	1,564	11,390	13.7
New Hampshire	533	3,020	17.6
New Jersey	4,768	25,280	18.9
New Mexico	820	6,800	12.1
New York	30,945	72,640	42.6
North Carolina	4,158	32,490	12.8
North Dakota	164	1,520	10.8
Ohio	4,931	40,320	12.2
Oklahoma	860	11,030	7.8
Oregon	2,757	19,750	14.0
Pennsylvania	8,800	36,490	24.1
Puerto Rico	245	9,700	2.5
Rhode Island	897	3,880	23.1
South Carolina	1,249	10,390	12.0
South Dakota	104	910	11.4
Tennessee	2,691	22,460	12.0
Texas	18,050	123,790	14.6
Utah	1,500	6,840	21.9
Vermont	288	1,060	27.2
Virginia	3,267	31,430	10.4
Washington	8,986	40,050	22.4
West Virginia	380	5,250	7.2
Wisconsin	2,021	12,980	15.6
Wyoming	80	890	9.0

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2019	
Alabama	1,907	11,020	17.3
Alaska	236	1,780	13.3
Arizona	4,825	25,780	18.7
Arkansas	794	5,130	15.5
California	43,952	165,030	26.6
Colorado	4,434	25,120	17.7
Connecticut	2,805	9,560	29.3
Delaware	488	4,400	11.1
District of Columbia	6,077	12,950	46.9
Florida	22,439	125,330	17.9
Georgia	8,999	39,030	23.1
Hawaii	857	4,360	19.7
Idaho	487	4,790	10.2
Illinois	17,190	55,860	30.8
Indiana	3,097	22,170	14.0
Iowa	1,473	4,760	30.9
Kansas	944	5,060	18.7
Kentucky	1,669	12,990	12.8
Louisiana	4,221	15,920	26.5
Maine	658	3,950	16.7
Maryland	5,218	27,300	19.1
Massachusetts	10,212	24,900	41.0
Michigan	4,552	29,570	15.4
Minnesota	4,317	21,720	19.9
Mississippi	959	4,530	21.2
Missouri	3,634	18,370	19.8
Montana	272	2,290	11.9
Nebraska	637	2,180	29.2
Nevada	2,266	11,390	19.9
New Hampshire	656	3,020	21.7
New Jersey	5,955	25,280	23.6
New Mexico	1,100	6,800	16.2
New York	36,285	72,640	50.0
North Carolina	5,671	32,490	17.5
North Dakota	202	1,520	13.3
Ohio	6,393	40,320	15.9
Oklahoma	1,230	11,030	11.2
Oregon	3,396	19,750	17.2
Pennsylvania	10,546	36,490	28.9
Puerto Rico	348	9,700	3.6
Rhode Island	1,133	3,880	29.2
South Carolina	1,788	10,390	17.2
South Dakota	151	910	16.6
Tennessee	4,020	22,460	17.9
Texas	23,898	123,790	19.3
Utah	2,029	6,840	29.7
Vermont	348	1,060	32.8
Virginia	4,686	31,430	14.9
Washington	10,864	40,050	27.1
West Virginia	610	5,250	11.6
Wisconsin	2,678	12,980	20.6
Wyoming	99	890	11.1

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–September)		
Alabama	1,808	11,020	16.4
Alaska	221	1,780	12.4
Arizona	4,758	25,780	18.5
Arkansas	811	5,130	15.8
California	40,094	165,030	24.3
Colorado	4,293	25,120	17.1
Connecticut	2,306	9,560	24.1
Delaware	421	4,400	9.6
District of Columbia	5,684	12,950	43.9
Florida	30,104	125,330	24.0
Georgia	8,907	39,030	22.8
Hawaii	811	4,360	18.6
Idaho	579	4,790	12.1
Illinois	14,883	55,860	26.6
Indiana	2,849	22,170	12.9
Iowa	1,359	4,760	28.6
Kansas	859	5,060	17.0
Kentucky	1,510	12,990	11.6
Louisiana	3,390	15,920	21.3
Maine	601	3,950	15.2
Maryland	4,572	27,300	16.7
Massachusetts	9,356	24,900	37.6
Michigan	4,322	29,570	14.6
Minnesota	3,881	21,720	17.9
Mississippi	923	4,530	20.4
Missouri	3,414	18,370	18.6
Montana	272	2,290	11.9
Nebraska	656	2,180	30.1
Nevada	2,269	11,390	19.9
New Hampshire	600	3,020	19.9
New Jersey	5,489	25,280	21.7
New Mexico	1,098	6,800	16.1
New York	31,753	72,640	43.7
North Carolina	5,713	32,490	17.6
North Dakota	197	1,520	13.0
Ohio	6,200	40,320	15.4
Oklahoma	1,344	11,030	12.2
Oregon	3,369	19,750	17.1
Pennsylvania	9,828	36,490	26.9
Puerto Rico	353	9,700	3.6
Rhode Island	1,086	3,880	28.0
South Carolina	1,884	10,390	18.1
South Dakota	127	910	14.0
Tennessee	4,511	22,460	20.1
Texas	24,867	123,790	20.1
Utah	2,078	6,840	30.4
Vermont	279	1,060	26.3
Virginia	4,747	31,430	15.1
Washington	10,567	40,050	26.4
West Virginia	490	5,250	9.3
Wisconsin	2,369	12,980	18.3
Wyoming	86	890	9.7

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

[a] Estimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Number of persons with PrEP indications in Puerto Rico is not available in 2017. 2018 data are used for 2017.

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2017		
Arizona			
Maricopa County	1,943	23,540	8.3
California			
Alameda County	1,464	7,260	20.2
Los Angeles County	9,834	64,180	15.3
Orange County	1,084	9,990	10.9
Riverside County	1,022	11,040	9.3
Sacramento County	587	5,460	10.8
San Bernardino County	438	12,450	3.5
San Diego County	2,477	19,420	12.8
San Francisco County	6,597	11,330	58.2
District of Columbia	4,018	13,710	29.3
Florida			
Broward County	2,011	20,030	10.0
Duval County	256	9,250	2.8
Hillsborough County	648	12,670	5.1
Miami-Dade County	2,018	22,190	9.1
Orange County	1,043	16,500	6.3
Palm Beach County	388	7,620	5.1
Pinellas County	470	10,470	4.5
Georgia			
Cobb County	277	3,570	7.8
DeKalb County	916	6,370	14.4
Fulton County	2,018	12,060	16.7
Gwinnett County	320	3,390	9.4
Illinois			
Cook County	8,905	38,270	23.3
Indiana			
Marion County	692	8,490	8.2
Louisiana			
East Baton Rouge Parish	225	1,290	17.4
Orleans Parish	1,061	5,230	20.3
Maryland			
Baltimore City	475	6,000	7.9
Montgomery County	567	5,790	9.8
Prince George's County	460	3,830	12.0
Massachusetts			
Suffolk County	1,944	7,050	27.6
Michigan			
Wayne County	695	9,470	7.3
Nevada			
Clark County	958	8,790	10.9
New Jersey			
Essex County	406	5,190	7.8
Hudson County	675	4,720	14.3

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2017 *(cont)*		
New York			
Bronx County	1,335	6,690	20.0
Kings County	4,867	15,300	31.8
New York County	9,911	14,790	67.0
Queens County	2,634	8,740	30.1
North Carolina			
Mecklenburg County	692	9,430	7.3
Ohio			
Cuyahoga County	612	8,200	7.5
Franklin County	1,360	13,660	10.0
Hamilton County	280	6,430	4.4
Pennsylvania			
Philadelphia County	2,475	8,550	28.9
Puerto Rico			
San Juan Municipio[d]	n/a	2,190	n/a
Tennessee			
Shelby County	319	7,590	4.2
Texas			
Bexar County	676	13,010	5.2
Dallas County	2,366	22,000	10.8
Harris County	2,602	39,780	6.5
Tarrant County	698	11,550	6.0
Travis County	2,244	10,810	20.8
Washington			
King County	5,072	13,690	37.0

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2018		
Arizona			
Maricopa County	2,968	22,720	13.1
California			
Alameda County	1,929	8,930	21.6
Los Angeles County	12,891	67,450	19.1
Orange County	1,640	10,510	15.6
Riverside County	1,454	11,080	13.1
Sacramento County	797	5,920	13.5
San Bernardino County	631	11,890	5.3
San Diego County	3,495	14,500	24.1
San Francisco County	8,176	10,840	75.4
District of Columbia	5,212	12,950	40.2
Florida			
Broward County	2,913	20,470	14.2
Duval County	382	8,970	4.3
Hillsborough County	1,152	12,910	8.9
Miami-Dade County	3,891	21,760	17.9
Orange County	1,895	15,310	12.4
Palm Beach County	594	9,170	6.5
Pinellas County	800	9,530	8.4
Georgia			
Cobb County	395	3,070	12.9
DeKalb County	1,229	6,290	19.5
Fulton County	2,667	13,120	20.3
Gwinnett County	468	3,240	14.4
Illinois			
Cook County	11,812	39,060	30.2
Indiana			
Marion County	880	9,150	9.6
Louisiana			
East Baton Rouge Parish	452	1,810	25.0
Orleans Parish	1,387	4,590	30.2
Maryland			
Baltimore City	666	6,330	10.5
Montgomery County	819	5,770	14.2
Prince George's County	662	4,040	16.4
Massachusetts			
Suffolk County	2,532	6,520	38.8
Michigan			
Wayne County	1,045	9,270	11.3
Nevada			
Clark County	1,320	11,670	11.3
New Jersey			
Essex County	600	4,090	14.7
Hudson County	896	4,650	19.3

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2018 *(cont)*		
New York			
Bronx County	2,045	5,570	36.7
Kings County	6,408	15,650	40.9
New York County	12,603	15,540	81.1
Queens County	3,412	9,230	37.0
North Carolina			
Mecklenburg County	1,001	8,450	11.8
Ohio			
Cuyahoga County	832	7,520	11.1
Franklin County	1,679	11,620	14.4
Hamilton County	449	7,720	5.8
Pennsylvania			
Philadelphia County	3,306	9,840	33.6
Puerto Rico			
San Juan Municipio	n/a	2,190	n/a
Tennessee			
Shelby County	480	6,450	7.4
Texas			
Bexar County	1,140	11,920	9.6
Dallas County	3,354	28,670	11.7
Harris County	3,971	40,670	9.8
Tarrant County	1,197	11,340	10.6
Travis County	3,450	11,590	29.8
Washington			
King County	6,360	17,890	35.6

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Arizona			
Maricopa County	3,725	22,720	16.4
California			
Alameda County	2,254	8,930	25.2
Los Angeles County	14,679	67,450	21.8
Orange County	2,123	10,510	20.2
Riverside County	1,861	11,080	16.8
Sacramento County	987	5,920	16.7
San Bernardino County	805	11,890	6.8
San Diego County	3,962	14,500	27.3
San Francisco County	9,170	10,840	84.6
District of Columbia	6,077	12,950	46.9
Florida			
Broward County	3,881	20,470	19.0
Duval County	524	8,970	5.8
Hillsborough County	1,495	12,910	11.6
Miami-Dade County	6,668	21,760	30.6
Orange County	2,845	15,310	18.6
Palm Beach County	915	9,170	10.0
Pinellas County	1,133	9,530	11.9
Georgia			
Cobb County	584	3,070	19.0
DeKalb County	1,616	6,290	25.7
Fulton County	3,403	13,120	25.9
Gwinnett County	714	3,240	22.0
Illinois			
Cook County	14,027	39,060	35.9
Indiana			
Marion County	1,171	9,150	12.8
Louisiana			
East Baton Rouge Parish	514	1,810	28.4
Orleans Parish	1,669	4,590	36.4
Maryland			
Baltimore City	930	6,330	14.7
Montgomery County	982	5,770	17.0
Prince George's County	853	4,040	21.1
Massachusetts			
Suffolk County	3,181	6,520	48.8
Michigan			
Wayne County	1,293	9,270	13.9
Nevada			
Clark County	1,944	11,670	16.7
New Jersey			
Essex County	715	4,090	17.5
Hudson County	1,105	4,650	23.8

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019 *(cont)*		
New York			
Bronx County	2,305	5,570	41.4
Kings County	7,645	15,650	48.8
New York County	14,508	15,540	93.4
Queens County	4,020	9,230	43.6
North Carolina			
Mecklenburg County	1,420	8,450	16.8
Ohio			
Cuyahoga County	996	7,520	13.2
Franklin County	2,126	11,620	18.3
Hamilton County	570	7,720	7.4
Pennsylvania			
Philadelphia County	3,781	9,840	38.4
Puerto Rico			
San Juan Municipio	n/a	2,190	n/a
Tennessee			
Shelby County	656	6,450	10.2
Texas			
Bexar County	1,529	11,920	12.8
Dallas County	4,325	28,670	15.1
Harris County	5,055	40,670	12.4
Tarrant County	1,513	11,340	13.3
Travis County	4,654	11,590	40.2
Washington			
King County	7,669	17,890	42.9

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–September)		
Arizona			
Maricopa County	3,678	22,720	16.2
California			
Alameda County	1,921	8,930	21.5
Los Angeles County	14,079	67,450	20.9
Orange County	2,041	10,510	19.4
Riverside County	1,804	11,080	16.3
Sacramento County	891	5,920	15.1
San Bernardino County	744	11,890	6.3
San Diego County	3,614	14,500	24.9
San Francisco County	7,828	10,840	72.2
District of Columbia	5,684	12,950	43.9
Florida			
Broward County	5,720	20,470	27.9
Duval County	645	8,970	7.2
Hillsborough County	1,642	12,910	12.7
Miami-Dade County	8,869	21,760	40.8
Orange County	3,433	15,310	22.4
Palm Beach County	2,435	9,170	26.6
Pinellas County	1,064	9,530	11.2
Georgia			
Cobb County	592	3,070	19.3
DeKalb County	1,580	6,290	25.1
Fulton County	3,297	13,120	25.1
Gwinnett County	724	3,240	22.3
Illinois			
Cook County	12,069	39,060	30.9
Indiana			
Marion County	1,066	9,150	11.7
Louisiana			
East Baton Rouge Parish	488	1,810	27.0
Orleans Parish	1,255	4,590	27.3
Maryland			
Baltimore City	813	6,330	12.8
Montgomery County	880	5,770	15.3
Prince George's County	759	4,040	18.8
Massachusetts			
Suffolk County	2,969	6,520	45.5
Michigan			
Wayne County	1,143	9,270	12.3
Nevada			
Clark County	1,921	11,670	16.5
New Jersey			
Essex County	648	4,090	15.8
Hudson County	1,006	4,650	21.6

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–September) *(cont)*		
New York			
Bronx County	1,848	5,570	33.2
Kings County	6,714	15,650	42.9
New York County	12,940	15,540	83.3
Queens County	3,562	9,230	38.6
North Carolina			
Mecklenburg County	1,498	8,450	17.7
Ohio			
Cuyahoga County	881	7,520	11.7
Franklin County	2,129	11,620	18.3
Hamilton County	567	7,720	7.3
Pennsylvania			
Philadelphia County	3,224	9,840	32.8
Puerto Rico			
San Juan Municipio	n/a	2,190	n/a
Tennessee			
Shelby County	691	6,450	10.7
Texas			
Bexar County	1,562	11,920	13.1
Dallas County	4,685	28,670	16.3
Harris County	5,409	40,670	13.3
Tarrant County	1,486	11,340	13.1
Travis County	4,622	11,590	39.9
Washington			
King County	7,520	17,890	42.0

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

[a] Estimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018, 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Number of persons with PrEP indications in San Juan Municipio is not available in 2017. 2018 data are used for 2017.

Table 7. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	**Puerto Rico**[a]	Alabama
Maricopa County	San Juan Municipio[a]	Arkansas
California		Kentucky[a]
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey[b]		
Essex County[b]		
Hudson County[b]		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 7. Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania[a]		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic: A Plan for America initiative, see https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview.

[a] Linkage to care and viral suppression data are not provided for states and associated counties that have incomplete reporting of laboratory data to CDC: Kansas, Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[b] Linkage to care and viral suppression data are not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral load laboratory results: New Jersey.